Review
article
Harnessing
the
power
of
arti
fi
cial
intelligence
in
pharmaceuticals:
Current
trends
and
future
prospects
Saha
Aritra
a
,
b
,
Chauhan
Baghel
Shikha
b
,
Singh
Indu
b
,
*
a
Department
of
Pharmaceutical
Science
&
Technology,
Birla
Institute
of
Technology,
Mesra,
Jharkhand,
835215,
India
b
Amity
Institute
of
Pharmacy,
Amity
University,
Amity
Rd,
Sector
125,
Noida,
Uttar
Pradesh,
201301,
India
A
R
T
I
C
L
E
I
N
F
O
Keywords:
Arti
fi
cial
intelligence
Pharmaceuticals
Drug
discovery
Predictive
modeling
Precision
medicine
Automation
Machine
learning
Deep
learning
Natural
language
processing
A
B
S
T
R
A
C
T
Introduction
of
arti
fi
cial
intelligence
(AI)
technology
in
the
fi
eld
of
pharmaceutical
industry
has
been
driven
to
discovery and development of drugs, also personalized medicine. In this article The review investigates systematic
trends
facing
AI-powered
transformation.
AI
has
improved
ef
fi
ciency
by
reducing
the
drug
development
time,
costs and success rates due to machine learning (ML), deep learning (DL) and natural language processing (NLP).
The literature search was conducted systematically, using core scienti
fi
c databases to source data-mining research
studies
on
predictive
modelling,
virtual
screening,
and
automation
in
AI
applications.
Findings
here
underscore
the
critical
role
that
AI
plays
in
precision
medicine,
as
well
as
process
optimization
in
manufacture,
but
ethical
issues and privacy of data and regulations add signi
fi
cantly to hurdles. The study con
fi
rms that AI presents unique
opportunities
for
developing
personalized
healthcare
and
answering
global
health
challenges,
nonetheless
its
adoption involves overcoming ethical and regulatory issues beautiful collaboration and agreeing to industry wide
standards.
The
next-generation
products
bring
hope
for
low-cost,
patient-centric
solutions
indicating
pharma-
ceutical
landscape
phases
of
the
paradigm.
1.
Introduction
The
phrase
arti
fi
cial
intelligence
(AI)
describes
the
creative
applica-
tion
of
computer
systems
to
carry
out
tasks
that
would
normally
need
human intelligence. It is a compelling and transformative concept. These
jobs require a broad range of skills, which AI systems perform with ease,
including
learning,
analyzing,
reasoning,
and
decision-making.
Surpris-
ingly, AI systems fall neatly into categories like rule-based expert systems
and sophisticated machine learning methods like
decision trees.
1
Robotics is one example of how end-to-end solutions for dosage form
manufacture
might
be
facilitated.
With
the
least
amount
of
human
intervention
possible,
these
state-of-the-art
systems
ef
fi
ciently
manage
the
laborious
task
of
loading
re
fi
ned
pharmacological
compounds
into
machines
and
simultaneously
retrieving
the
fi
nished
goods.
The
phar-
maceutical manufacturing industry has surely seen a revolution because
to
this
outstanding
usage
of
AI,
which
has
streamlined
and
accelerated
production
processes
like
never
before.
2
The
goal
of
this
work
is
to
examine
how
arti
fi
cial
intelligence
(AI)
is
altering
drug
research
and
development
(
r
&
D)
procedures.
It
also
explores
the
signi
fi
cant
possibil-
ities by which AI can be used to improve our knowledge of illnesses and,
eventually, the health of humans
and animals.
3
Unquestionably,
throughout
the
past
few
decades,
the
pharmaceu-
tical
industry's
overall
success
in
drug
r
&
D
and
cost
ef
fi
ciency
have
gradually
decreased.
The
pharmaceutical
industry
is
facing
a
growing
number
of
obstacles,
including
increased
healthcare
expenses.
4
This
is
the
exact
moment
that
arti
fi
cial
intelligence
(AI)
steps
in
as
a
game-changer.
AI
presents
a
previously
unheard-of
chance
to
improve
the
cost-effectiveness
and
success
rate
of
research
and
development
of
new medications.
5
,
6
The
adoption
of
arti
fi
cial
intelligence
(AI)
by
the
pharmaceutical
sector marks a turning point in our pursuit of improved health outcomes.
With
arti
fi
cial
intelligence,
we
have
an
opportunity
to
completely
transform
the
pharmaceutical
industry
and
bring
in
a
new
era
of
inno-
vation, cost-effectiveness,
and enhanced human and animal health.
7
1.1.
De
fi
nition
of
arti
fi
cial
intelligence
in
pharmaceuticals
Self-learning
is
a
fundamental
and
pivotal
component
within
the
realm of arti
fi
cial intelligence (AI), and owing to the perpetual and ever-
changing
nature
of
the
pharmaceutical
industry,
this
distinctive
trait
of
AI
renders
it
impeccably
suited
for
this
particular
sector.
8
An
intricate
and
protracted
process
of
drug
development,
it
typically
requires
a
*
Corresponding
author.
E-mail
address:
induysingh@gmail.com
(S.
Indu).
Contents lists available at
ScienceDirect
Intelligent
Pharmacy
journal
homepage:
www.keaipublishing.com/en/journals/intelligent-pharmacy
https://doi.org/10.1016/j.ipha.2024.12.001
Received
29
April
2022;
Received
in
revised
form
5
July
2022;
Accepted
8
July
2022
Available
online
xxxx
2949-866X/
©
2025
The
Authors.
Publishing
services
by
Elsevier
B.V.
on
behalf
of
Higher
Education
Press
and
KeAi
Communications
Co.
Ltd.
This
is
an
open
access
article
under
the
CC
BY-NC-ND
license
(
http://creativecommons.org/licenses/by-nc-nd/4.0/
).
Intelligent
Pharmacy
xxx
(xxxx)
xxx
Please
cite
this
article
as:
Aritra
S
et
al.,
Harnessing
the
power
of
arti
fi
cial
intelligence
in
pharmaceuticals:
Current
trends
and
future
prospects,
Intelligent Pharmacy, https://doi.org/10.1016/j.ipha.2024.12.001
staggering
span
of
approximately
12
–
15
years
and
incurs
an
exorbitant
average cost of around $314 million to $4.46 billion per newly developed
drug.
9
Astonishingly,
a
mere
2
out
of
10
drugs
will
ultimately
generate
revenues
surpassing
or
at
the
very
least
mirroring
the
research
and
development
(
r
&
D)
costs.
A
prime
example
lies
in
the
unequivocal
collaboration between P
fi
zer and IBM in 2015, as they jointly embarked
upon harnessing the unbridled capabilities of IBM's AI platform, Watson,
with
the
aim
of
stimulating
a
more
streamlined
and
ef
fi
cient
develop-
ment
of
novel
immuno-therapy
drugs.
10
Watson
strives
towards
this
momentous
objective
through
its
ability
to
furnish
an
all-encompassing
and
immensely
sophisticated
arti
fi
cial
intelligence
system,
which
not
only
facilitates
the
production
of
conclusive
and
incontrovertible
data
but
also
enables
the
formulation
of
pinpoint
and
meticulous
recom-
mendations.
11
–
14
The integration of AI is not without its challenges such
as
data
privacy,
algorithm
bias,
regulatory
considerations,
and
ethical
implications must be carefully navigated to ensure that the bene
fi
ts of AI
in
pharmaceuticals
are realized
while minimizing potential risks.
15
Nevertheless,
with
the
rapid
advancements
in
AI
technology,
the
pharmaceutical industry has an unprecedented opportunity to transform
and revolutionize itself in ways that were previously unimaginable.
16
By
embracing
and
harnessing
the
power
of
AI,
pharmaceutical
companies
can
unlock
new
insights,
accelerate
the
pace
of
drug
discovery,
and
ul-
timately improve patient outcomes. As the possibilities and applications
of AI continue to evolve, the future of the pharmaceutical industry looks
brighter than ever
before.
17
,
18
1.2.
Importance
of
arti
fi
cial
intelligence
in
pharmaceuticals
Firstly,
the
development
of
a
hybrid
application
combining
support
vector machines and simulated annealing to create a predictive model for
oral
bioavailability
of
drugs
represents
an
innovative
approach
that
has
tangibly contributed to enhancing the effectiveness and ef
fi
ciency of the
drug development process.
19
Secondly, a notable application involves the
discovery
of
new
enzymes
for
non-ribosomal
peptide
synthesis,
a
fundamental
aspect
of
drug
production,
potentially
leading
to
a
remarkable
expansion
of
therapeutic
options
available.
Lastly,
the
introduction
of
an
advanced
robotic
system
has
revolutionized
the
syn-
thesis of small molecules in organic chemistry or chemical biology. This
automation not only expedites the process but also signi
fi
cantly improves
accuracy and reproducibility.
19
These remarkable achievements
achieved through the integration of
AI
in
the
pharmaceutical
industry
have
sparked
a
growing
interest
and
recognition
of
its
immense
potential
among
pharmaceutical
researchers
and
executives.
20
In
June
2009,
it
is
intriguing
to
note
that
industry
analyst Datamonitor predicted a signi
fi
cant surge in the pharmaceutical
industry's
investment
in
AI.
The
report
projected
that
the
industry's
expenditure on AI would more than double, soaring from $880 million in
2008
to
surpass
an
astounding
$60
billion
by
2030.
This
optimistic
estimation further underscores the growing recognition of the invaluable
role that AI can play in revolutionizing the pharmaceutical industry.
21
As
the
pharmaceutical
industry
unabashedly
embraces
AI,
it
is
poised
to
revolutionize the pharmaceutical landscape, ultimately advancements in
medical science that bene
fi
t
humanity as
a whole.
22
1.3.
Scope
of
the
study
This
review
provides
a
comprehensive
overview
and
detailed
evalu-
ation
of
the
extensive
application
of
arti
fi
cial
intelligence
in
pharma-
ceutical
research
and
development.
It
identi
fi
es
and
explores
the
vast
innovative
potential
for
AI
in
various
areas.
Moreover,
AI
computer
systems,
including
robotic
automation,
data
analysis,
and
clinical
trial
management,
are
thoroughly
examined
to
understand
their
profound
impact
on
transforming
the
conventional
methods
of
pharmaceutical
discovery,
development,
and
marketing.
The
review
examines
the
bal-
ance
between
opportunity
costs
and
the
increased
ef
fi
ciency
and
pro-
ductivity
that
AI
technologies
are
expected
to
bring
to
the
pharmaceutical
industry,
ultimately
assessing
whether
these
advance-
ments
will
lead
to
a
net
socioeconomic
bene
fi
t.
Overall,
this
compre-
hensive
review
serves
as
a
guiding
resource
for
understanding
the
vast
potential
of
AI
in
the
pharmaceutical
industry.
It
tackles
various
facets,
including
research,
development,
job
market
impact,
and
personalized
medicine,
while
thoroughly
analyzing
the
advantages
and
potential
socio-economic
implications.
1.4.
Methods
A structured and exhaustive search strategy was implemented in this
review
to
compile
pertinent
literature
regarding
the
pharmaceutical
industry's
utilization
of
arti
fi
cial
intelligence
(AI).
A
comprehensive
search
was
carried out
in
order to
fi
nd peer-reviewed articles published
in
the
last
ten
years
(2013
–
2023)
throughout
the
main
scienti
fi
c
data-
bases, such as PubMed, Scopus, and Web of Science. To narrow down the
search
results,
Boolean
operators
(AND,
OR)
were
coupled
with
key-
words
like
“
AI
in
pharmaceuticals,"
“
drug
discovery
with
AI,"
“
machine
learning in healthcare," and
“
AI applications
in drug development."
Studies that demonstrated AI technologies, such as machine learning,
deep
learning,
and
natural
language
processing,
in
fi
elds
like
drug
dis-
covery,
precision
medicine,
and
pharmaceutical
production
were
the
main
emphasis
of
the
inclusion
criteria.
Included
were
studies
that
addressed implementation, ethical, and regulatory issues.
Articles that were not in English, had no bearing on AI applications in
medicine,
or
were
entirely
theoretical
without
any
scienti
fi
c
or
techno-
logical analysis
were excluded based on exclusion criteria.
Despite
not
adhering
to
the
PRISMA
guidelines,
a
complex
and
iter-
ative method was employed for the selection of articles, which involved
several
rounds
of
screening
full
texts,
abstracts,
and
titles
to
guarantee
quality
and
relevance.
Finding
signi
fi
cant
trends,
technical
de-
velopments,
and
their
possible
effects
on
the
industry
were
the
main
goals
of
the
data
extraction
process.
This
approach
guaranteed
a
thor-
ough
examination
of
AI's
revolutionary
impact
on
medicines during
the
previous ten years.
2.
Applications
of
arti
fi
cial
intelligence
in
pharmaceuticals
Clinical trials optimization is another area which AI has tremendous
in
fl
uence
in.
By
harnessing
the
power
of
machine
learning,
AI
can
effectively
identify
suitable
participants
for
clinical
trials
by
matching
them
to
a
set
of
complex
eligibility
criteria.
23
Machine
learning
algo-
rithms
can
compare
potential
candidates
to
a
trial
using
pattern
recog-
nition and classify similar patients with common conditions or diseases.
This breakthrough has improved the selection process and increasing the
chances of successful trials.
24
Precision Medicine, the practice of tailoring
treatments
to
individual
patients.
To
create
individualized
treatments,
meticulous data
analysis plays
a
crucial
role,
and
this
is
where machine
learning
algorithms
excel.
25
This
potential
game-changer
in
precision
medicine lies in the utilization of patient-speci
fi
c data and the integration
of
this
data
with
relevant
treatment
guidelines.
21
AI
offers
a
myriad
of
applications in this
fi
eld, including the repurposing of existing drugs for
different conditions. Through the mining of vast data sets, AI can identify
potential
alternative
uses
for
drugs,
opening
up
new
possibilities
for
treatment.
26
Additionally, AI's ability to conduct
‘
virtual screening' plays
a
vital
role
in
drug
discovery.
AI
accelerates
the
screening
process,
ulti-
mately
reducing
the
high
rate
of
failure
in
drug
development.
27
A
remarkable example of AI's impact in drug development is IBM Watson.
In collaboration with P
fi
zer, IBM Watson developed a machine learning
model that compares gene mutations in cancer cells with data from cells
exposed to a range of
substances.
18
,
28
–
30
2.1.
Drug
discovery
and
development
Arti
fi
cial intelligence
has been quite important
in
drug development
and
discovery
of
late.
There
are
numerous
technologies
available
to
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
2
scientists,
but
the
one
that
will
be
introduced
in
this
essay
is
the
appli-
cation
of
arti
fi
cial
intelligence.
This
is
because
of
the
fact
that
arti
fi
cial
intelligence is a computational model designed to mimic human thought
processes
in
an
analytical
manner.
31
There
are
no
effective
methods
of
prevention
for
running
a
global
campaign
and
recruiting
talent
from
around
the
world
at
all
stages
of
drug
development.
32
With
an
ever-growing database of genomics and drug discovery information, this
area
is
pushing
for
new
high-throughput
screening,
An
example
of
this
would be something like the in
fl
uenza virus. It kills between 250,000 and
500,000
people
globally
each
year,
and
current
antiviral
drugs
are
effective
but
rising
rates
of
resistance
are
making
them
less
effective.
15
High-throughput
technology
allows
combinatorial
chemistry
and
screening of a huge number of chemicals for their effectiveness in as short
a time as possible. This can be coupled with an AI model that attempts to
predict resistance and viral mutagenicity, in order to try and create drugs
that will be effective longer term and cost less to develop. The approach is
to use modern technology to model new methods of administration and
drug
effects
on
immunity,
attempting
to
shift
the
balance
from
always
trying
to
play
catch
up
with
vaccines
and
treatments,
to
one
where
dis-
ease prevention is viable for developing
world demographics.
12
Model-based technology all the way through to clinical trials will be
necessary if these aims are to be achieved. By harnessing the power of AI
and its ability to analyze vast amounts of data, researchers can expedite
the
drug
discovery
process,
identify
potential
drug
targets,
and
predict
their
ef
fi
cacy
with
higher
accuracy.
16
By
analyzing
patient data
and
ge-
netic factors, it can tailor treatment plans to individual patients, ensuring
the
highest
chance
of
success
while
minimizing
adverse
reactions.
33
Furthermore,
the
use
of
AI
in
drug
development
extends
beyond
tradi-
tional
pharmaceuticals.
It
can
be
employed
in
the
development
of
personalized medicine.
21
The
application
of
arti
fi
cial
intelligence
in
drug
development
holds
tremendous
promise
for
advancing
medical
research
and
improving
global health outcomes.
34
,
35
Widely used AI model tools are described in
Table 1
.
2.2.
Precision
medicine
With
machine
learning
techniques,
computers
have
the
ability
to
analyze vast amounts of data and unveil intricate relationships that might
go
unnoticed
by
human
eyes.
In
the
fi
elds
of
genetics
and
molecular
biology,
which
serve
as
the
fundamental
sciences
of
precision
medicine,
the data manifests in the form of gene sequences, expression levels, and an
array
of
measurements.
36
On
the
other
hand,
the
information
embedded
within
medical
records,
in
the
form
of
unstructured
text,
ranging
from
progress notes
to imaging
and
other test reports.
37
,
38
The
ultimate objec-
tive of machine learning in the
fi
eld of medicine is to discover the rules and
logic
that
a
decision
maker
would
employ
if
they
had
ample
time
to
meticulously
analyze
all
the
available
evidence.
39
,
34
Precision
medicine,
which is also known as personalized medicine, represents an approach to
patient
care
that
enables
doctors
to
select
treatments
with
the
highest
likelihood of helping patients, based on a comprehensive understanding of
the
genetic aspects of their
disease.
40
In order to achieve
precision medi-
cine,
we
must
accumulate
vast
amounts
of
information
about
our
indi-
vidual
patients
and
possess
the
capability
to
categorize
patients
and
diseases in an exceedingly precise
manner compared to our
current
prac-
tices.
41
This is where arti
fi
cial intelligence (AI) and machine learning step
in to enable
us
to gather diverse and disparate
data,
subsequently
identi-
fying
intricate
patterns
and
relationships
that
provide
the
necessary
comprehension for precision medicine to
fl
ourish.
42
,
33
2.3.
Clinical
trials
optimization
In a futuristic world full of advanced technology and innovation, the
realm
of
clinical
trials
is
striving
for
swiftness,
cost-effectiveness,
and
enhanced
ef
fi
cacy.
Thankfully,
the
realm
of
arti
fi
cial
intelligence
(AI)
provides
hope for
the
realization of
this
desire.
Clinical trials
stand
as
a
crucial foundation for the evaluation and validation of novel treatments,
making it imperative to identify and employ strategies that yield optimal
results.
43
The
journey
of
a
clinical
trial
comprises
multiple
stages,
each
presenting its own unique challenges. These stages include study design,
patient
recruitment,
data
monitoring,
and
analysis,
all
playing
pivotal
roles
in
the
course
of
a
trial's
progression.
44
Patient
recruitment,
in
particular, has
been a
focal point, as it
holds a high
potential
for failure
when
it
comes
to
testing
experimental
drugs
or
therapies
vis-
a-vis
their
pre-existing counterparts.
45
However, with the advent of AI, a signi
fi
cant
transformation
in
recruitment
ef
fi
ciency
becomes
conceivable,
poten-
tially revolutionizing the landscape of clinical trials.
46
Despite
the
remarkable
capacity
of
AI
to
enhance
recruitment
pro-
cesses, challenges may arise when attempting to improve other stages of
Table
1
Description
of
popular AI
model
tools.
AI
Model
Tools
Summary
DeepChem
An open-source library offering a large selection
of
drug
discovery
tools and
models,
such
as
generative
chemistry,
virtual screening,
and
deep learning
algorithms
for predicting
chemical
properties.
SMILES Transformer
A
deep learning
model
that
creates
molecular
structures
from
Standardized
Molecular
Input
Line Entry System (SMILES) texts as input. Lead
optimization and de novo drug development are
two
applications
for
it.
RDKit
An
established
open-source
chemo-informatics
library
with
many
functions
for
handling
molecules,
fi
nding
substructures,
and
calculating
descriptors.
It
can
be
included
into
drug
discovery
applications
using
machine
learning
frameworks.
Schr
€
odinger
Suite
A
full-featured
drug
discovery
software
suite
that includes
a
number
of
AI-powered
capabilities.
It
has
modules
for drug
design
based
on
ligands
and
structures,
virtual
screening,
molecular
modeling,
and
predictive
modeling.
ChemBERTa
A linguistic paradigm created especially for tasks
involving
drug
development.
Relying
on
the
Transformer
architecture,
it
can synthesize
molecular
structures,
forecast
attributes,
and
help
optimize
leads
thanks to
pre-trained
data
from
a
vast
corpus of
chemical
and
medicinal
literature.
IBM RXN
for Chemistry
Chemical
reaction
prediction
using an
arti
fi
cial
intelligence
model.
It
helps in
the development
of
new
synthetic
pathways
and compound
synthesis
by
generating
possible reaction
outcomes using deep learning algorithms as well
as massive
reaction
databases.
GraphConv
An architecture for a model of deep learning that
uses molecular graphs. By utilizing the structural
data contained in the graphical representation of
molecules, it has proved successful in predicting
chemical attributes like toxicity and bioactivity.
scape-DB
A
database
called scape-DB
(Extraction
of
Chemical
and
Physical
Properties
from
the
Literature-DrugBank) uses machine learning and
natural language processing to extract biological
and chemical information
from
scholarly
publications.
It offers
useful
data
for studies
on
medication
discovery.
AutoDock
Vina
A
well-known
docking
program
that forecasts
the
binding
af
fi
nity
of
small
compounds
and
protein
targets
using machine
learning
approaches.
It can
help
with lead
optimization
and virtual
screening
in
the drug
discovery
process.
GENTRL
(Generative
Tensorial
Reinforcement
Learning)
A
deep learning
algorithm
that
builds new
molecules
with the
desired
properties
by fusing
generative
chemistry
and
reinforcement
learning. It has been applied to the optimization
and de
novo design
of
drugs.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
3
clinical
trials.
This
is
due
to
the
inherent
reliance
on
algorithms
to
analyze
vast
quantities
of
data
for
generating
accurate
insights.
47
Achieving
success
in
these
areas
necessitates
overcoming
the
conserva-
tive attitudes of clinicians who harbor a belief in their own capabilities,
as
well
as
addressing
concerns
regarding
the
costs
and
acceptance
sur-
rounding automation. Moreover, the complexity of fully comprehending
algorithms
poses
a
potential
risk.
48
Thus,
the
development
of
AI
in
the
scope
of
clinical
trials
mandates
careful
consideration
and
measures
to
ensure
adequate
comprehension
and
minimizing
any
inherent
dan-
gers.
49
,
50
However,
various
challenges
must
be addressed to
extend AI's
in
fl
uence
throughout
all
stages
of
clinical
trials,
necessitating
the
navi-
gation of attitudinal barriers, cost considerations, and the risks associated
with
algorithmic reliance.
51
2.4.
Pharmacovigilance
and
adverse
event
monitoring
Regarding
an
original
study,
the
term
arti
fi
cial
intelligence
(AI)
was
fi
rst present at a conference at Dartmouth College in 1956. By simulating
intelligence through the use of computers and related technology, AI has
the
potential
to
greatly
enhance
problem-solving
abilities,
reasoning
skills,
and
knowledge
acquisition.
Furthermore,
AI
has
the
capability
to
revolutionize
the
healthcare
industry
by
providing
meaningful
pattern
recognition
and
valuable
insights
from
complex
data.
In
fact,
AI
tech-
niques
have
already
proven
their
worth
by
being
utilized
for
the
devel-
opment and analysis of data from research and development, as well as in
identifying
patterns
in
disease
states
and
therapy
through
clinical
research studies.
52
Researchers believe that AI could potentially analyze
trial
and
error
studies
and
patient
records
in
order
to
predict
which
treatment options will be most effective for future patients with speci
fi
c
diseases.
53
Another area in which AI is making signi
fi
cant contributions
is pharmacovigilance.
54
,
55
With the help of automated databases, AI has
been able to facilitate and improve the drug safety surveillance process,
especially in spontaneous reporting systems. These systems allow for the
detection of signals indicating potential adverse effects from various data
sources.
AI
applications
in
signal
detection
include
Bayesian
inference,
data
mining,
knowledge-based
systems,
and
information
retrieval.
56
AI,
particularly
through
the
use
of
natural
language
processing
and
knowl-
edge representation techniques, lays a solid foundation for the extraction
of adverse event and safety data from large text-based data sources. This
method,
known as intelligent data analysis. It
can
be
classi
fi
ed
into
two
main
types:
statistical
analyses
and
more
advanced
“
hypothesis-gener-
ating"
analyses.
57
Statistical
analyses
focus
on
fi
nding
relationships
be-
tween
drugs
and
outcomes,
as
well
as
quantifying
them,
while
“
hypothesis-generating" analyses are aimed at revealing new information
about
suspected
associations or new
drugs.
58
,
59
3.
Challenges
and
limitations
of
arti
fi
cial
intelligence
in
pharmaceuticals
One
of
the
major
concerns
in
the
fi
eld
of
modern
medicine
is
the
interpretation of recent EU regulations and other regulatory measures in
terms
of
their
impact
on
it.
This
is
particularly
true
of
arti
fi
cial
intelli-
gence
(AI).
60
The
development
and
deployment
of
AI
applications
in
medicine
can
potentially
revolutionize
the
entire
health-care
ecosystem
and
is
facing
a
rapidly
increasing
number
of
vendors
and
stakeholders
invested
in
its
success.
61
This
general
lack
of
regulation
means
that
de-
velopers
often
do
not
consider
certain
issues
because
they
are
not
yet
accustomed
to
thinking
of
AI
as
a
method
not
a
tool.
62
,
63
This
lack
of
awareness
led
to
a
number
of
violations,
and
it
is
likely
that
the
same
thing will happen in AI development if developers are not given speci
fi
c
guidelines.
The
lack
of
standardization
is
related
to
the
lack
of
regula-
tion.
64
,
65
The
introduction
of
AI
algorithms
into
healthcare
raises
com-
plex
ethical
questions
regarding
privacy,
security,
and
the
potential
for
biased outcomes. It is imperative that developers are equipped with the
knowledge and tools to address these ethical concerns.
66
Finally, in order
to share and aggregate data to train AI algorithms, there must be a uni
fi
ed
system for data representation. This represents
an order given the sheer
variety of existing medical data.
67
Cooperation and collaboration among
various
stakeholders,
including
healthcare
providers,
researchers,
and
technology companies, will be essential to establish a standardized data
representation framework.
68
Regardless, it is essential that the necessary
measures are
taken
to ensure the
responsible
and effective
implementa-
tion of
AI in
the medical
fi
eld.
69
3.1.
Data
privacy
and
security
concerns
Privacy and integrity of information are critical issues in AI, machine
learning, and data security. It is imperative to address concerns about the
misuse
and
leakage
of
valuable
proprietary
data,
especially
within
the
pharmaceutical industry.
70
The potential disaster that can arise from the
breach
of
sensitive
information
is
a
cause
for
alarm.
Aside
from
the
pharmaceutical sector, there are also worries surrounding the security of
private
medical
and
clinical
trial
data.
71
Looking
ahead,
there
is
a
risk
that data protection legislation in the future may inadvertently hinder the
advancement
of
AI
in
healthcare
and
pharmaceuticals.
72
The
tight
re-
strictions
imposed
on
the
use
of
medical
data
could
make
it
dif
fi
cult
to
effectively
train
algorithms,
thus
limiting
their
potential
in
improving
patient outcomes and revolutionizing the industry. A notable example of
data
protection
legislation
is
the
European
Union's
General
Data
Pro-
tection
Regulation
(GDPR),
set
to
be
enforced
in
2018.
73
However,
its
impact
on
the
fi
eld
of
AI
in
healthcare
remains
uncertain, leaving
ques-
tions regarding its compatibility with technological advancements.
74
It is
essential
to
continue
exploring
comprehensive
solutions
that
prioritize
both privacy and innovation, ensuring that future legislation aligns with
the
evolving
landscape
of
AI
and
its
potential
contributions
to
the
betterment of society
66
,
75
,
76
3.2.
Ethical
considerations
An IBM research project, conducted by a team of dedicated scientists,
delved
into
the
intricate
realm
of
machine
learning
as
it
pertains
to
medical
decision
support
systems.
This
enlightening
investigation
un-
covered
compelling
evidence
of
discrimination
that
can
occur
within
these
systems,
particularly
when
catering
to
speci
fi
c
subpopulations.
35
Speci
fi
cally, the study centered on a model designed to aid in treatment
decisions for individuals grappling with complex chronic kidney disease.
Surprisingly, the results revealed a disheartening disparity in the way the
system responded to African American patients, even when there was an
intentional
omission
of
racial
information
from
the
algorithm.
77
–
79
The
revolutionary
capability
to
automate
repetitive
tasks
or
predictively
intervene
to
mitigate
disease
progression
presents
an
incredible
oppor-
tunity for health systems to optimize ef
fi
ciency and
fi
nancial resources.
80
However,
the
ethical
dilemma
arises
when
the
aforementioned
cost
savings
become
disproportionately
burdened
upon
a
speci
fi
c
group
or
individual as a result of decisions derived from AI. Such a scenario, where
one group bears a greater share of the
fi
nancial implications, is inherently
perceived
as
unfair
and
inherently
unethical.
81
–
83
Thus,
this
ground-
breaking
research
serves
as
a
clarion
call
to
rectify
the
inherent
biases
and potential injustices embedded within the realms of machine learning
and
AI-driven
decision-making.
By
addressing
and
mitigating
these
im-
balances,
we
can
strive
towards
a
future
where
technological
advance-
ments truly serve humanity as a whole, ensuring equitable treatment and
fostering a just society.
84
–
88
3.3.
Lack
of
standardization
and
regulation
Another major issue is the global nature of arti
fi
cial intelligence (AI)
and
healthcare.
The
utilization
of
AI
and
data
is
not
con
fi
ned
to
any
speci
fi
c region, as they can easily cross borders.
68
,
88
However, this global
nature
of
AI
in
healthcare
poses
challenges
in
terms
of
determining
regulatory
boundaries.
It
becomes
dif
fi
cult
to
discern
what
falls
under
regulatory oversight and what doesn't. Additionally, there is uncertainty
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
4
about the applicability of data privacy and localization laws to various AI
products
and
datasets.
89
They
learn
from
their
environment
in
unpre-
dictable
ways,
making
it
challenging,
if
not
impossible,
to
determine
a
fi
xed
underlying
mechanism.
90
,
91
Consequently,
a
drug
or
treatment
developed using machine learning may not be a static product, but rather
an
ongoing
subscription
that
provides
updated
recommendations.
The
conventional
approach
of
pre-market
clinical
trials,
designed
to
ensure
the
safety
and
ef
fi
cacy
of
medical
products,
may
have
limited
applica-
bility to AI.
92
Arti
fi
cial intelligence is increasingly
fi
nding applications in
healthcare,
particularly
in
the
fi
elds
of
drug
development
and
personal-
ized treatments.
93
The immense potential of AI in these areas necessitates
the
establishment
of
regulatory frameworks
that
account for
the unique
nature of healthcare data and recognize the potential consequences of AI
product
failures.
94
In
2017,
the
FDA
introduced
an
innovation
pathway
with
the
aim
of
regulating
AI
and
machine
learning-based
medical
de-
vices.
This
initiative
involves
the
development
of
novel
regulatory
frameworks,
tools,
and
assessment
methods
to
evaluate
these
devices
effectively.
95
,
96
4.
Current
trends
in
arti
fi
cial
intelligence
in
pharmaceuticals
Current
machine
learning
strategies
could
use
these
methods
and
make
utilization
of
real
datasets
regarding
the
compound
in
order
to
learn
the
most
predictive
function.
This
ranges
from
general
supervised
strategies
to
support
vector
machines,
to
more
particular
methods,
for
example, simulated event of the function inside a speci
fi
c environment.
97
To
understand
this-a
given
compound
in
fl
uences
the
disease,
the
approach utilized as a part of predictive learning through step 2 has been
to
connect
between
features
of
the
compound
and
its
impact
on
the
disease using a function, frequently graphically.
98
Coming these methods
will
lessen
the time
and
cost
for
new
drug development
by
determining
the
best
probability
of
success
for
speci
fi
c
compounds
prior
to
testing
them. At that point, the methodology would recognize speci
fi
c features of
promising
compounds
to
known
successful
drugs.
99
Step
three
–
to
un-
derstand the signi
fi
cance of machine learning to pharmaceuticals. This is
just
a
study
of
an
algorithm
to
determine
its
effects
on
a
given
environ-
ment in this way it could be straightforwardly connected. Coming above,
this
could
run
simple
S.E.A
(Side
Effect
Assessment)
on
adverse/side
effect of a few potential drugs for a given disease.
100
The most compelling
space
is
simulation
of
a
given
drug
to
some
state
of
a
disease
and
its
potential
impact.
This
clearly
determines
a
wide
range
of
discoveries
with
the
aim
to
reinforce
that
AI,
particularly
machine
learning,
and
is
becoming progressively imperative in pharmaceuticals.
101
By leveraging
advanced
algorithms
and
real-world
data
sets,
we
can
unlock
the
po-
tential
of
predictive
functions
that
bridge
the
gap
between
compound
features
and
their
impact
on
diseases.
102
Implementing
these
cutting-edge methodologies will not only expedite the drug development
process but also signi
fi
cantly reduce costs.
33
By accurately assessing the
likelihood
of
success
for
speci
fi
c
compounds
before
extensive
testing,
valuable
resources
can
be
allocated
more
ef
fi
ciently.
Machine
learning
serves
as
a
vital
tool
for
algorithmic
analysis,
providing
invaluable
in-
sights
into
the
effects
of
various
compounds
within
speci
fi
c
environ-
ments.
2
This
allows
for
the
seamless
application
of
simple
S.E.A
(Side
Effect
Assessment)
on
potential
drugs
for
a
given
disease.
Additionally,
simulating
the
interaction
between
a
drug
and
a
diseased
state
offers
tremendous potential for discovering novel treatments and interventions.
By harnessing its capabilities, we stand on the brink of a new era, where
innovation and precision converge to yield transformative advancements
in
healthcare.
103
In the area of drug development, the prediction of potential new drugs
to diseases is currently receiving a signi
fi
cant amount of attention, and for
good
reason.
97
By
accurately
predicting
the
effectiveness
of
a
drug,
re-
searchers and scientists can not only save substantial amounts of money on
research
and
development
costs,
but
also
drastically
reduce
the
time
it
takes
to
bring
a
new
drug
to
the
market.
104
Historically,
this
prediction
process has been divided into two distinct stages. The
fi
rst stage
involves
conducting
tests
to
determine
if
a
compound
has
a
natural
impact
on
a
particular disease. These
tests
can
range from
traditional wet
lab
biology
methods
to
more
innovative
approaches
such
as
data
mining
techniques
that utilize
a
vast amount
of diverse data,
including gene
and protein
se-
quences from disease-affected tissues.
105
The wide range of methodologies
available
for
this
stage
makes
it
incredibly
versatile
and
suitable
for
comprehensive data analysis. However, it is important to note that despite
the
diversity
of
approaches,
their
ultimate
goal
remains
the
same
–
to
identify
compounds
that
have
a
real
potential
to
combat
the
targeted
disease.
Once
a
compound
has
been
identi
fi
ed
as
having
a
potential
impact, it progresses to the second stage.
106
This stage involves developing
a method for the compound to be tested or utilized as a drug for the speci
fi
c
disease. This step is crucial in the drug development process as it lays the
foundation for further testing and validation.
107
,
108
The overall process of
drug
development
is
intricate
and
multifaceted,
requiring
collaboration
between
experts
from
various
fi
elds,
such
as
biology,
chemistry,
and
medicine.
109
The
success
of
each
stage
heavily
relies
on
the
accurate
analysis
of
data
and
the
implementation
of
innovative
techniques.
16
As
technology
continues
to
advance,
the
fi
eld
of
drug
development
further
evolves,
paving
the
way
for
more
ef
fi
cient
and
effective
approaches
to
predicting and developing new drugs for diseases.
3
,
11
,
12
4.1.
Machine
learning
and
predictive
analytics
In the pharmaceutical industry, the rapid growth in the abundance of
biomedical
data
has
sparked
a
signi
fi
cant
demand
for
applications
of
arti
fi
cial
intelligence
(AI).
14
Among
the
various
domains,
machine
learning
stands
out
as
a
fi
eld
capable
of
making
remarkable
advance-
ments.
By
employing
sophisticated
algorithms
to
learn
from
data,
ma-
chine
learning
enables
the
generation
of
predictions
and
informed
decisions.
98
Within the pharmaceutical landscape, this technology can be
effectively utilized to construct models that identify patterns within data.
Consequently,
these
fi
ndings
can
be
leveraged
to
discover
novel
drug
targets
or
ascertain
which
patients
are
likely
to
respond
favorably
to
speci
fi
c
treatments.
110
Thus,
it
serves
as
a
crucial
element
in
the
devel-
opment
of
personalized
medicine.
111
Early
initiatives
in
this
sphere
include
a
groundbreaking
study
aiming
to
predict
the
likelihood
of
schizophrenia
diagnosis
by
analyzing
pertinent
health
conditions
in
pa-
tients.
Furthermore,
a
pioneering
model
has
been
created
to
determine
the
probability
of
drug
withdrawal
from
the
market
by
evaluating
its
properties and adverse events reported.
112
Notably, both of these notable
examples
utilize
publicly
available
data
derived
from
clinical
trials,
epidemiological
studies,
and
adverse
event
databases.
113
Within
the
pharmaceutical industry, machine learning
fi
nds wider application in the
realm
of
in-silico
modeling.
This
comprehensive
term
encompasses
an
extensive range of
mathematical modeling techniques that facilitate the
simulation
or
prediction
of
drug
behavior
and/or
disease
states.
12
For
instance,
a
model
has
been
developed
to
forecast
the
probability
of
encountering adverse cardiac events associated with new drugs.
114
This
innovation has the potential to proactively detect safety concerns during
drug
development
or
even
eliminate
unnecessary
safety
warnings
for
drugs
with
low
associated
risks.
115
Through
these
transformative
appli-
cations, machine learning continues to revolutionize the pharmaceutical
industry,
fostering
advancements
in
drug
discovery,
safety
evaluation,
and personalized healthcare.
116
4.2.
Natural
language
processing
and
text
mining
One
of
the
main
dif
fi
culties
involved
in
extracting
information
from
clinical
notes
is
the
wide
range
of
language
used
by
healthcare
pro-
fessionals,
which
includes
complex
medical
terminology.
Clinical
text
consists of various ambiguous terms, abbreviations, acronyms, as well as
instances
of
negation
and
speculation.
117
–
119
For
example,
consider
the
following
sentence:
“
It
is
possible
that
the
patient
may
have
early-stage
pneumonia."
The
context
in
which
this
sentence
is
expressed
is
extremely
important.
120
The
mention
of
possibility
implies
that
the
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
5
diagnosis is still uncertain and could change. Ongoing research in Natural
Language
Processing
(NLP) aims
to
develop
tools
that
can
identify
such
terms
and
automatically
transform
the
text
into
a
representation
that
preserves the information while getting rid of the original wording.
121
In
recent
years,
due
to
remarkable
technological
advancements,
there
has
been
a
signi
fi
cant
increase
in
the
amount
of
clinical
data
that
is
avail-
able.
122
A
large
proportion
of
this
data
is
in
the
unstructured
form.
By
applying
NLP
techniques
to
this
type
of
data,
it
becomes
possible
to
convert unstructured information into well-organized structured data.
123
This
process
not
only
simpli
fi
es
the
analysis
of
medical
information
but
also
enables
making
accurate
predictions
about
potential
negative
re-
actions
to
medications,
medical
procedures,
and
a
wide
range
of
other
medical
outcomes.
124
However,
clinical
notes
present
numerous
chal-
lenges,
these
challenges
require
extensive
exploration
and
implementa-
tion
of
advanced
NLP
algorithms
to
ensure
accurate
extraction
and
interpretation
of
clinical
data,
125
ultimately
leading
to
improved
healthcare outcomes
and patient care.
126
4.3.
Image
recognition
and
computer
vision
Computer vision, as a subset of software engineering, offers numerous
advantages
compared
to
traditional
image
processing
techniques.
This
makes
it
highly
suitable
for
applications
in
the
pharmaceutical
and
medical
fi
elds.
127
However,
the
aim
is
to
replace
macroscopic
and
microscopic
examinations
with
more
ef
fi
cient
and
informed
diagnostic
tools
through
the
use
of
extensive
medical
image
databases.
128
The
pri-
mary
focus
lies
on
automating
the
analysis
of
intricate image data,
thus
signi
fi
cantly
reducing
the
burden
on
healthcare
professionals.
129
High
content
screening
(HCS),
a
technique
that
enables
the
simultaneous
evaluation
of
multiple
cellular
parameters,
generates
an
overwhelming
number of images in a single experiment, often described as
“
extracting a
phenotypic
readout".
130
This
fl
ood
of
data
requires
sophisticated
and
highly
ef
fi
cient
image
analysis
algorithms
to
extract
meaningful
infor-
mation and patterns.
131
On the other hand, we are also deeply interested
in examining clinical data, including images of tissue samples, for disease
diagnosis.
132
Although
the
translation
of
these
processes
into
clinical
practice
is
still
in
the
early
stages,
there
is
immense
potential
for
revo-
lutionizing healthcare and improving patient outcomes.
133
–
136
5.
Future
prospects
of
arti
fi
cial
intelligence
in
pharmaceuticals
Community
well-being
programs
established
through
the
gathering
and analysis of collective data, automatically taxonomize and stored with
subsequent
retrieval
possibilities,
can
also
become
an
AI
learning
expe-
rience.
137
AI
would
thus
implement
an
effective
community
health
management
plan
by
providing
people
resources
and
information
on
implementing lifestyle changes to better public and individual health.
138
Wearable
devices
and
software
programs
that
utilize
AI
to
derive
data
obtained from various patient sources will steer humanity towards more
ef
fi
cient
illness
prevention
and
management
of
current
health
condi-
tions.
139
,
140
A
patient
similarity
AI
model
developed
by
BioXcel
used
unsupervised
learning
to
analyze
data
from
70,000
patients,
including
unstructured
data
from
patient
history
reports.
141
This
led
to
the
devel-
opment
of
an
algorithm
that
could
rapidly
match
patients
with
appro-
priate clinical trials or treatments.
With
AI
virtual
simulation,
concept
testing,
and
other
AI
algorithm
methods, this is predicted to increase ef
fi
cacy and con
fi
dence by reducing
development time and cost by up to 70 %, with a higher 10 % increase in
approval
rates
of
new
drugs.
142
,
143
Future
prospects
of
AI
in
pharma-
ceuticals
are
bright.
The
current
new
drug
development
platform
is
time-consuming,
high-costing,
and
inef
fi
cient.
It
takes
an
average
of
12
years from discovery to market.
144
The cost of new drug development is
estimated to range from $109 million to $2 billion, with not even a 100 %
success rate on human or animal tests. Considering only 5 in 5000 drugs
progress
to
pre-clinical
trials.
This
is
largely
due
to
the
limitations
of
human clinical trials and error.
145
,
146
5.1.
Integration
of
arti
fi
cial
intelligence
with
internet
of
things
(IoT)
The
Internet
of
Things
(IoT)
refers
to
the
interconnection
of
computing
devices
embedded
in
everyday
objects
that
enable
them
to
send
and
receive
data.
Current
trends
show
that
homes,
cars,
and
con-
sumer products are just a few examples of items that are becoming part of
the IoT ecosystem.
147
In healthcare, there is much interest in IoT and how
it
can
be
used
to
improve
patient
care.
With
the
growing
number
of
in-
dividuals
with
chronic
diseases
and
conditions,
healthcare
is
shifting
from hospital-based care to home and community-based care.
148
A shift
to
home-based
care
means
a
greater
burden
of
disease
management
is
being
placed
on
the
patient
who
is
often
ill-equipped
for
the
task.
IoT
devices designed to aid in disease management could provide a bridge for
this gap in care. For the pharmaceutical industry, more patient-generated
data
means
a
greater
opportunity
to
understand
the
patient
and
the
ef-
fects
of
treatments
in
the
real
world.
149
AI
and
IoT
can
be
integrated in
multiple ways to track and analyze data in patients with chronic diseases.
One simple example is the tracking of medication adherence. It is well
understood
that
adherence
to
medications
for
chronic
diseases
is
poor,
with
roughly
50
%
of
patients
not
taking
their
medications
as
pre-
scribed.
81
Missed
doses
directly
lead
to
increased
disease
complications
and
hospitalizations,
which
are
costly
to
the
patient
and
the
healthcare
provider. Smart pill bottles are an example of an IoT device that could be
used
to
track
adherence.
150
The
bottle
can
detect
when
it
has
been
opened
and
closed
and
relay
that
information
to
an
application
that
stores
the
data.
83
AI
can
be
applied
to
analyze
this
data
and
send
re-
minders
to
patients
who
have
missed
doses.
In
a
case
study
involving
stroke
patients,
it
was
found
that
simple
mobile
phone
reminders
signi
fi
cantly
increased
adherence.
86
AI
can
take
this
a
step
further
and
analyze when patients are missing doses and look for patterns as to why
the doses are being missed. In this way, interventions can be designed to
target speci
fi
c
problems
in individual patients.
5.2.
Personalized
medicine
and
treatment
planning
In the realm of personalized medicine, these innovative methods must
undergo
extensive
and
stringent
clinical
testing
and
regulatory
scrutiny
in
order
to
ensure
their
safety
and
ef
fi
cacy.
147
This
groundbreaking
po-
tential
would
undoubtedly
bring
about
a
profound
and
transformative
shift
in
the
landscape
of
evidence-based
medicine,
blurring
the
bound-
aries
that
have
traditionally
delineated
the
realms
of
AI
and
clinical
research.
148
Renowned
expert
Peter
Szolovits
of
MIT
envisions
a
future
where
the
practice
of
medicine
undergoes
a
revolutionary
trans-
formation.
He
asserts,
“
In
the
long
run,
we
cannot
simply
continue
practicing
medicine
as
we
have
done
so
far.
The
solution
lies
in
har-
nessing
the
power
of
computerization
and
extracting
meaningful
and
actionable conclusions from the vast amount of information available to
us.".
149
Therefore, it seems highly likely that these advanced technologies
will gradually assume greater decision-making responsibilities in various
domains of healthcare.
150
Over recent years, there has been a noticeable
and
discernible
shift
towards
tailoring
treatment
regimens
and
thera-
peutic approaches to suit the unique genetic makeup and speci
fi
c disease
characteristics
of
individual
patients.
This
increasingly
popular
approach,
commonly
referred
to
as
personalized
medicine,
recognizes
that
each
patient
is
distinct
and
requires
a
personalized
analysis
and
treatment
plan.
151
This
is
precisely
where
the
immense
potential
of
arti
fi
cial
intelligence
comes
to
the
front.
152
Arti
fi
cial
intelligence
has
already
demonstrated
signi
fi
cant
promise
and
potential
in
aiding
the
interpretation,
integration,
and
analysis
of
complex
data
derived
from
sources
such
as
the
human
genome,
disease
chemistry,
and
biological
responses
to
treatments.
153
In
particular,
machine
learning
approaches
have
showcased
their
remarkable
ability
to
identify
intricate
patterns,
extract
crucial
attributes,
and
discover
valuable
insights
from
data
that
would
otherwise
elude
human
analysts.
154
These
data-centric
and
AI-driven
approaches
have
the
potential
to
revolutionize
personalized
disease
treatment
by
closely
aligning
with
the
analysis
of
intricate
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
6
datasets
in
order
to
derive
and
foster
the
most
optimal
and
evidence-based
clinical decisions.
155
,
156
5.3.
Intelligent
drug
delivery
systems
The
implementation
of
arti
fi
cial
intelligence
(AI)
in
drug
delivery
is
now
a
reality
and
marks
the
beginning
of
a
revolutionary
shift.
Micro
particles
are
commonly
used
to
transport
drugs
to
their
intended
sites,
but
automating
this
process
using
conventional
programming
methods
has
been
challenging.
157
However,
with
the
use
of
neural
networks,
motion
can
be
programmed
in
micro
particles,
allowing
for
precise
and
complex
movements
under
varying
external
conditions.
Pohly's
essay
demonstrates the effectiveness of
using neural networks and fuzzy logic
to control the movement of simulated micro robots and particles in a Java
program.
Additionally,
the
study
highlights
the
increased
accuracy
and
reliability
of
drug
release
compared
to
conventional
methods.
158
The
ability
to
program
step-by-step
drug
release
through
changes
in
the
microenvironment
is
also
a
promising
application.
While
this
level
of
micro drug release is still in development, the potential of this technique
is signi
fi
cant.
159
,
160
It is evident that smart drug delivery systems combine bio-compatible
devices
and/or
appliances
with
drug
delivery
systems
to
automate
and
regulate
the
medicine
administration
process
in
the
body.
161
Through
advancements
in
neural
networks,
the
motion
of
micro
particles
can
be
programmed
to
ensure
targeted
drug
release.
This
ability
to
simulate
precise
and
complex
movements
under
varying
external
conditions
en-
hances
the
ef
fi
ciency
and
reliability
of
drug
delivery.
162
One
notable
application
is
the
use
of
AI
in
intelligent
drug
delivery
systems,
which
integrate
bio-compatible
devices
and/or
appliances
with
drug
delivery
systems
to
automate
and
regulate
medicine
administration
in
the
body.
159
The
emergence
of
smart
drug
delivery
systems
represents
a
signi
fi
cant advancement in pharmaceutical technology. This integration
of
intelligent
technology
addresses
the
challenges
of
precise
drug
tar-
geting
and
personalized
medicine
administration,
ultimately
improving
treatment
outcomes
and
patient
care
through
automation
and
regulation.
158
In this section, the role of the healthcare professional is set to change
with the use of AI tools, the diagnostic process and therapeutic decision
making
will
become
more
data
driven.
161
,
162
It
should
result
in
the
prevention
of
adverse
events,
the
avoidance
of
misdiagnosis
and
the
generation
of
tailored
treatment
plans.
163
However,
this
change
to
evidence-based
practice
will
require
healthcare
professionals
to
have
a
broad
of
the
methodologies
used
to
derive
conclusions
in
speci
fi
c
AI
applications. Treatment plans which are based on complex data analysis
may be dif
fi
cult to comprehend for the patient.
78
This would make it hard
to
obtain
informed
consent
for
the
treatment
process.
With
speci
fi
c
reference
to
clinical
research,
AI
tools
have
the
potential
to
automate
clinical
trials,
through
intelligent
trial
design,
patient
recruitment,
and
data collection and analysis.
164
The use of historical data in this context
has both positive and negative implications. The ability to learn from past
mistakes
to
improve
trial
design
and
the
analysis
of
large-scale
data
to
fi
nd
new
insights
into
diseases,
are
clear
bene
fi
ts.
165
However,
the
automation
of
aspects
of
the
clinical
trial
may
lead
to
a
loss
of
clinical
research posts and less
opportunity for
research training.
5.4.
Impact
on
healthcare
professionals
Healthcare
practitioners
must
adapt
to
the
integration
of
AI
in
their
daily
responsibilities.
To
effectively
utilize
AI,
healthcare
professionals
must place their trust in the technology and recognize it as a reliable tool
for
generating
data.
166
It
is
crucial
to
demonstrate
that
technology
and
humans
can
collaborate
to
deliver
optimal
healthcare.
This
can
be
accomplished
by
incorporating
AI
education
into
medical
school
curricula
and
integrating
AI
into
continuing
education
programs
for
practicing healthcare professionals.
167
,
168
For instance, AI can be utilized
to analyze patient electronic health records and propose a diagnosis for a
patient
complaint.
169
However,
it
is
imperative
for
healthcare
practi-
tioners to comprehend the extent of AI's role and not rely solely on it to
perform tasks that they are capable of completing themselves.
170
Lastly, healthcare professionals must consider the implications that AI
will
bring
to
patient
care.
This
encompasses
both
the
potential
bene
fi
ts
and
drawbacks
it
may
have
for
their
patients,
as
well
as
how
it
might
impact their
approach to patient care.
133
,
171
,
172
5.5.
Economic
and
business
considerations
There are many ways in which AI can help reduce costs, but one of the
largest
areas
is
through
the
process
of
clinical
trials.
32
One
article
sug-
gests that using AI in the drug development stage could have a signi
fi
cant
impact
on
costs.
157
Drug
development
makes
up
a
third
of
total
clinical
trial expenditure, suggesting that around $37 billion would be saved on
an annual basis by implementing AI. This would not only reduce the cost
of
healthcare
for
the
patient,
it
could
also
increase
the
speed
at
which
drugs
are
developed.
173
The
added
speed
of
drug
development
can
be
attributed to the fact that AI can perform tasks much faster than a human
and
has
the
capacity
to
multitask.
172
An
example
of
this
would
be
the
system
developed
by
Berg
Health,
which
can
scan
the
vast
knowledge
contained within biology in order to form and test the main hypotheses of
a
clinical
trial
in
a
fraction
of
the
time
that
it
would
take
a
team
of
researchers.
174
An increase in the speed of drug development and a decrease in costs
of
clinical
trials
could
lead
to
an
overall
decrease
in
drug
prices.
This
could however lead to a decrease in revenue for the top pharmaceutical
companies.
117
Increased
mergers
and
acquisitions
may
in
fact
increase
industry ef
fi
ciency by maximizing the strength of combining companies
and ridding the industry of weaker ones.
35
,
117
,
175
This is already evident
through the combination of AI and big data approaches to form a virtual
brain
trust
of
several
companies
with
the
common
goal
of
bringing
col-
lective knowledge to a singular industry.
176
–
178
5.6.
Patient
empowerment
and
engagement
AI
chatbots
are
an
emerging
technology
with
great
potential
for
engaging patients. This is evident from the increasing use of chatbots in
fi
elds
like
eCommerce
and
customer
service.
179
Wearable
devices
can
collect
a
wider
range
of
data
about
a
patient's
daily
habits
and
physio-
logical state passively. This data can then be used to provide personalized
feedback
to
the
patient
in
a
timely
manner.
Particularly
in
certain
pop-
ulations
like
the
elderly
or
those
with
memory
impairment,
who
may
struggle
to
input
data
into
an
app,
these
devices
can
be
extremely
bene
fi
cial.
180
Mobile
apps,
on
the
other
hand,
hold
great
promise
in
helping
patients
understand
and
manage
their
medical
conditions.
Pa-
tients
can easily track
their symptoms, medications, and health
metrics,
and
receive
personalized
information
about
their
condition
through
these apps.
181
,
182
However,
the
concept
of
patient
empowerment
has
gained
impor-
tance
in
healthcare due
to the
rising prevalence
of
chronic diseases. Pa-
tients
believe
that
the
healthcare
system
should
be
more
focused
on
meeting
their
needs.
183
Extensive
research
indicates
that
empowered
patients
achieve
better
health
outcomes
and
incur
lower
healthcare
costs.
184
Patients
who
are
better
informed
and
involved
take
more
re-
sponsibility
for
their
health,
communicate
better
with
their
healthcare
providers,
and
seek
more
information
and
assertiveness
in
their
in-
teractions with the healthcare system.
185
–
187
5.7.
Recommendations
for
industry
adoption
of
AI
in
pharmaceuticals
To
accelerate
the
integration
of
Arti
fi
cial
Intelligence
(AI)
into
the
pharmaceutical
industry,
the
following
concrete
recommendations
are
proposed:
Pilot
Programs
and
Feasibility
Studies:
Launch
pilot
initiatives
in
particular
stages
of
drug
research,
such
predictive
modeling
or
virtual
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
7
screening. With this strategy, businesses may evaluate AI's capabilities in
safe
settings and
compare the
results
to
those
obtained using more
con-
ventional techniques.
Collaborative
Ecosystems:
Form
alliances
between
academic
in-
stitutions,
regulatory
agencies,
pharmaceutical
businesses,
and
AI
tech-
nology companies. These kinds of partnerships help
fi
ll knowledge gaps
in
the
use
of
AI
by
combining
resources,
encouraging
creativity,
and
facilitating information transfer.
Infrastructure
Development
:
Make
investments
in
cutting-edge
computational
infrastructure,
including
cloud-based
platforms
and
high-performance
computing
(HPC)
devices.
These
are
necessary
for
effectively
organising
huge
datasets
and
executing
intricate
AI
algorithms.
Regulatory
Readiness
:
To
guarantee
adherence
to
changing
stan-
dards,
involve
regulatory
bodies
early
in
the
AI
development
process.
Approvals
for
AI-driven
approaches
can
be
accelerated
by
creating
vali-
dation frameworks tailored to AI.
Skill
Development
:
Employees
should
be
trained
to
effectively
operate
AI
systems
and
interpret
their
results.
Professionals
in
r
&
D,
production,
and
quality
assurance
should
be
the
focus
of
upskilling
programs in order to close the knowledge gap between domain expertise
and AI.
Data
Governance
:
To
guarantee
data
security,
quality,
and
adher-
ence
to
privacy
laws,
implement
strong
data
governance
principles.
AI
models will be able to produce trustworthy and objective
fi
ndings if data
collecting and annotation procedures are standardized.
Ethical
and
Transparent
AI
Deployment
:
Create
policies
that
handle
ethical
issues
like
decision
openness,
data
privacy,
and
algo-
rithmic bias. In addition to fostering trust, ethical AI methods will reduce
the likelihood of unfavourable consequences.
Phased Implementation
: Before branching out to more intricate and
resource-intensive
fi
elds
like
personalized
medicine,
start
with
AI
ap-
plications
that
offer
an
instant
return
on
investment,
such
virtual
screening in drug discovery or predictive maintenance in manufacturing.
Performance
Metrics
:
De
fi
ne
precise,
quanti
fi
able
standards
for
assessing
the
effectiveness
of
AI
applications.
To
show
the
value
of
AI,
metrics
like
shorter
development
times,
cost
savings,
and
increased
predictive accuracy should be
monitored.
Open
Innovation
Platforms
:
Establish
or
take
part
in
open-access
platforms
that
allow
stakeholders
to
exchange
insights,
datasets,
and
algorithms. This collaborative approach can drive collective progress and
reduce duplication of efforts in
AI research.
By adopting these strategies, the pharmaceutical industry can harness
AI's
full
potential
to
enhance
innovation,
optimize
resource
utilization,
and improve global health outcomes.
6.
Conclusion
The
recent
years
of
rapid
development
in
the
area
of
arti
fi
cial
intel-
ligence
and
related
areas,
including
data
mining,
image
analysis,
and
robotics,
have
provided
abundant
opportunities
for
the
utilization
of
AI
in
pharmaceutical
research
and
development.
As
the
fi
eld
continues
to
evolve,
the
advancements
in
AI
are
paving
the
way
for
groundbreaking
innovations
in
various
domains
within
the
pharmaceutical
in-
dustry.
188
,
189
The work presented in this paper, while signi
fi
cant, is just a
glimpse
into
the
vast
potential
of
AI
in
pharmaceutical
research
and
development. It represents only a spectrum of the ongoing efforts in this
rapidly growing
fi
eld.
The
interest
in
data
mining
and
knowledge
discovery
for
use
in
de-
cision
support
has
also
gained
considerable
momentum
in
recent
years.
This
trend
highlights
the
importance
of
leveraging
AI
to
extract
mean-
ingful
information
from
massive
datasets
and
using
it
to
inform
critical
decisions
in
medicine.
190
To
achieve
this,
the
implementation
of
computer-based
methods
at
multiple
stages
of
the
research
and
devel-
opment process is indispensable.
168
AI-powered tools and techniques will
empower
researchers
to
navigate
the
immense
complexity
of
biological
systems
and
accelerate
the
discovery
of
innovative
therapies.
191
,
192
However, the journey of AI in the pharmaceutical industry is not without
challenges.
Additionally,
the
validation
and
regulatory
approval
of
AI-driven solutions pose unique considerations that need to be addressed
to
ensure
patient
safety
and
the
ef
fi
cacy
of
the
developed
treat-
ments.
193
,
194
The
true
testing
ground
for
AI
lies
in
its
ability
to
comprehensively
analyze
complex
interactions
and
pathways
at
a
mo-
lecular level.
195
,
196
The
achievements
in these
endeavors will shape
the
future
landscape
of
the
pharmaceutical
industry
and
determine
the
perceived value of AI for the industry as a whole.
197
,
198
Exciting times lie
ahead
as
we
witness
AI's
transformative
in
fl
uence
on
healthcare
and
its
profound implications for improving patient outcomes.
CRediT
authorship
contribution
statement
Saha Aritra:
Writing
–
original draft, Conceptualization.
Singh Indu:
Writing
–
review
&
editing.
Disclosure
statement
The
English
language
of
the
article
was
improved
with
ChatGPT,
OpenAI's
large-scale
language-generation
model.
Upon
generating
draft
language, the author reviewed, edited, and revised the language to their
own liking
and
takes ultimate responsibility
for
the
content of
this
pub-
lication. The authors declare no con
fl
ict of interest in the preparation and
publication
of
this
review
article,
“
Harnessing
the
Power
of
Arti
fi
cial
Intelligence
in
Pharmaceuticals: Current Trends
and Future Prospects.
”
Disclosure
statement
The
English
language
of
the
article
was
improved
with
ChatGPT,
OpenAI's
large-scale
language-generation
model.
Upon
generating
draft
language, the author reviewed, edited, and revised the language to their
own
liking
and
takes
ultimate
responsibility
for
the
content
of
this
publication.
Data
availability
This is a review article, and therefore, no new data were generated or
analysed
in
the
course
of
this
study.
All
information
and
data
discussed
are derived from previously published works, as cited within the article.
Ethics
approval
and
consent
to
participate
Not
applicable.
This
study
does
not
involve
any
human
or
animal
subjects.
Funding
details
Not Applicable.
Declaration
of
competing
interest
The
authors
declare
no
con
fl
ict
of
interest
in
the
preparation
and
publication
of
this
review
article,
“
Harnessing
the
Power
of
Arti
fi
cial
Intelligence
in
Pharmaceuticals: Current Trends
and Future Prospects."
Acknowledgments
The
authors
would
like
to
acknowledge
the
support
and
resources
provided by Amity Institute of Pharmacy, Amity University, U.P, India, in
facilitating
this
review
article.
Special
thanks
to
co-author
as
well
as
mentor
for
their
valuable
input,
which
contributed
to
the
insights
and
perspectives discussed in this article.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
8
References
1.
Laermann-Nguyen U, Back
fi
sch M.
Innovation Crisis in the Pharmaceutical Industry? A
Survey
.
SN
Business
&
Economics;
2021
.
2.
Sharma A, et al. A comprehensive
review on strategies for new drug discovery
and
enhanced
productivity
in
research
and
development:
recent
advancements
and
future
prospectives.
Mini-Reviews
Org
Chem
.
2021
May
1;18(3):361
–
382
.
3.
Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M.
How
much
does
it
cost
to
research
and
develop
a
new
drug?
A
systematic
review
and
assessment.
Pharmacoeconomics
.
2021
Nov;39:1243
–
1269
.
4.
Malandraki-Miller
S,
Riley
PR.
Use
of
arti
fi
cial
intelligence
to
enhance
phenotypic
drug
discovery.
Drug
Discov
Today
.
2021
Apr;26(4):887
–
901
.
5.
Gholoom
SI,
Zervopoulos
PD.
The
effect
of
mergers
and
acquisitions
on
ef
fi
ciency:
evidence
from
the
pharmaceutical
industry.
Adv
Sci
Technol
.
2023
Sep
29;129:
77
–
95
.
6.
Scannell
JW,
Bosley
J,
Hickman
JA,
et
al.
Predictive
validity
in
drug
discovery:
what
it
is,
why
it
matters
and
how
to
improve
it.
Nat
Rev
Drug
Discov
.
2022
Dec;
21(12):915
–
931
.
7.
Vogel
M,
Kakani
P,
Chandra
A,
Conti
RM.
Medicare
price
negotiation
and
pharmaceutical
innovation
following
the
In
fl
ation
Reduction
Act.
Nat
Biotechnol
.
2024
Mar;42(3):406
–
412
.
8.
Blanco-Gonzalez
A,
Cabezon
A,
Seco-Gonzalez
A,
et
al.
The
role
of
ai
in
drug
discovery:
challenges,
opportunities,
and
strategies.
Pharmaceuticals
.
2023
Jun
18;
16(6):891
.
9.
Boniolo
F,
Dorigatti
E,
Ohnmacht
AJ,
Saur
D,
Schubert
B,
Menden
MP.
Arti
fi
cial
intelligence
in
early
drug
discovery
enabling
precision
medicine.
Expet
Opin
Drug
Discov
.
2021
Sep
2;16(9):991
–
1007
.
10.
Kiriiri
GK,
Njogu
PM,
Mwangi
AN.
Exploring
different
approaches
to
improve
the
success
of
drug
discovery
and
development
projects:
a
review.
Future
J
Pharm
Sci
.
2020
Dec;6:1
–
2
.
11.
Khan SR, Al Rijjal D, Piro A, Wheeler MB. Integration of AI and traditional medicine
in
drug
discovery.
Drug
Discov
Today
.
2021
Apr;26(4):982
–
992
.
12.
Gupta
R,
Srivastava
D,
Sahu
M,
Tiwari
S,
Ambasta
RK,
Kumar
P.
Arti
fi
cial
intelligence
to
deep
learning:
machine
intelligence
approach
for
drug
discovery.
Mol
Divers
.
2021
Aug;25:1315
–
1360
.
13.
Qureshi R, Irfan M, Gondal TM, et al. AI in drug discovery and its clinical relevance.
Heliyon
.
2023
Jul;9(7):e17575
.
14.
Kolluri S, Lin J, Liu R, Zhang Y, et al. Machine learning and arti
fi
cial intelligence in
pharmaceutical research and development: a review.
AAPS J
. 2022 Jan 4;24(1):19
.
15.
Patel V, Shah M. Arti
fi
cial intelligence and machine learning in drug discovery and
development.
Intell
Med
.
2022;2:134
–
140
.
16.
Mak
KK,
Wong
YH,
Pichika
MR.
Arti
fi
cial
intelligence
in
drug
discovery
and
development.
Drug
Discovery
and
Evaluation:
Safety
and
Pharmacokinetic
Assays
.
2023
Sep
28:1
–
38
.
17.
Jim
enez-Luna J, Grisoni
F, Weskamp N, Schneider
G. Arti
fi
cial intelligence
in drug
discovery:
recent
advances
and
future
perspectives.
Expet
Opin
Drug
Discov
.
2021
Sep
2;16(9):949
–
959
.
18.
Pantin LP. Financial inclusion, cryptocurrency, and afrofuturism.
Nw. UL Rev.
2023;
118(3):621
–
659
.
19.
Drobak
JN.
Rethinking
Market
Regulation:
Helping
Labor
by
Overcoming
Economic
Myths
.
2021
.
20.
Hodge Jr
SD, Hubbard
JE. COVID-19: the
ethical and legal
implications
of
medical
rationing.
Gonzaga
Law
Rev
.
2020;56(159)
.
21.
Warburton
CES.
Economic
Analysis
and
Law:
The
Economics
of
the
Courtroom
.
2020
.
22.
Goshen
Z, Levit D.
Agents of
inequality:
common
ownership
and the decline
of
the
American
worker.
Duke
LJ
.
2022;72:1
–
69
.
23.
Atkinson R. When communities design aid: creating solutions to poverty that people
own.
Use
and
Need
.
2022
.
24.
Levin
Y.
GOVERNING
PRIORITIES.
25.
Martin
MR.
Bitcoin
versus
Fiat
Currency:
An
Ethical
Perspective
.
2021
.
26.
Vu
TNN.
The
Impact
of
Cryptocurrency
on
Traditional
Financial
Market
.
2022
.
27.
Jameaba
MS.
Digitalization,
emerging
technologies,
and
fi
nancial
stability:
challenges
and
opportunities
for
the
Indonesian
banking
sector
and
beyondMuyanja
Ssenyonga
Jameaba
.
Qeios;
2023
.
28.
Marks
M.
Biosupremacy:
big
data,
antitrust,
and
monopolistic
power
over
human
behavior.
UC
Davis
Law
Rev
.
2021;55(513)
.
29.
Drobak
JN.
Rethinking
Market
Regulation:
Helping
Labor
by
Overcoming
Economic
Myths
.
2021
.
30.
Jameaba
MS.
Digitalization,
Emerging
Technologies,
and
Financial
Stability:
Challenges
and
Opportunities
for
the
Indonesian
Banking
Industry
and
beyond
.
2022
.
31.
Farghali H, Canov
a NK, Arora M. The potential applications of arti
fi
cial intelligence
in
drug
discovery
and
development.
Physiol
Res
.
2021;Dec
30;70(Suppl4):
S715
–
S722
.
32.
Rashid
MB.
Arti
fi
cial
intelligence
effecting
a
paradigm
shift
in
drug
development.
SLAS
TECHNOLOGY:
Transl
Life
Sci
Innovat
.
2021
Feb;26(1):3
–
15
.
33.
Maharana
K,
Mondal
S,
Nemade
B.
A
review:
data
pre-processing
and
data
augmentation
techniques.
In:
Global
Transitions
Proceedings
.
2022
.
34.
Mchergui A, Moulahi T, Zeadally S. Survey on arti
fi
cial intelligence (AI) techniques
for
vehicular
ad-hoc
networks
(VANETs).
Veh
Commun
.
2022;34(3):100403
.
35.
Okoro ON, Hillman LA, Cernasev A. We get double slammed.
Healthcare experiences
of
perceived
discrimination
among
low-income
African-American
women.
Women
’
s
Health
.
2020
Jan-Dec;16,
1745506520953348
.
36.
Yang
Y, Zhuang
Y, Pan
Y. Multiple knowledge
representation
for big data
arti
fi
cial
intelligence:
framework,
applications,
and
case
studies.
Front
Information
Technol
Electron
Eng
.
2021
Dec;22(12):1551
–
1558
.
37.
Zhang
L,
Zhang
L.
Arti
fi
cial
intelligence
for
remote
sensing
data
analysis:
a
review
of
challenges
and
opportunities.
IEEE
Geosci
Rem
Sens
Mag
.
2022
Apr
13;10(2):
270
–
294
.
38.
Blasch
E,
Pham
T,
Chong
CY,
et
al.
Machine
learning/arti
fi
cial
intelligence
for
sensor
data fusion
–
opportunities
and challenges.
IEEE Aero Electron
Syst
Mag
. 2021
Jul
1;36(7):80
–
93
.
39.
Salcedo-Sanz
S,
Ghamisi
P,
Piles
M,
et
al.
Machine
learning
information
fusion
in
Earth
observation:
a
comprehensive
review
of
methods,
applications
and
data
sources.
Inf
Fusion
.
2020
Nov
1;63:256
–
272
.
40.
Agbehadji
IE,
Awuzie
BO,
Ngowi
AB,
Millham
RC.
Review
of
big
data
analytics,
arti
fi
cial
intelligence
and
nature-inspired
computing
models
towards
accurate
detection
of
COVID-19
pandemic
cases
and
contact
tracing.
Int
J
Environ
Res
Publ
Health
.
2020
Aug;17(15):5330
.
41.
Mishra
S,
Tyagi
AK.
The
role
of
machine
learning
techniques
in
internet
of
things-
based
cloud
applications.
In:
Arti
fi
cial
Intelligence-Based
Internet
of
Things
Systems
.
2022
.
42.
Minh
D,
Wang
HX,
Li
YF,
Nguyen
TN.
Explainable
arti
fi
cial
intelligence:
a
comprehensive
review.
Artif
Intell
Rev
.
2022;55:503
–
3568
.
43.
Unger
JM,
Hershman
DL,
Till
C,
et
al.
“
When
offered
to
participate
”
:
a
systematic
review
and
meta-analysis
of
patient
agreement
to
participate
in
cancer
clinical
trials.
JNCI:
J
Natl
Cancer
Inst
.
2021
Mar
1;113(3):244
–
257
.
44.
von
Dach
E,
Albrich
WC,
Brunel
AS,
et
al.
Effect
of
C-reactive
protein
–
guided
antibiotic
treatment
duration,
7-day
treatment,
or
14-day
treatment
on
30-day
clinical
failure
rate
in
patients
with
uncomplicated
gram-negative
bacteremia:
a
randomized
clinical
trial.
JAMA
.
2020
Jun
2;323(21):2160
–
2169
.
45.
Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated
heart
failure
with
volume
overload.
N
Engl
J
Med
.
2022
Sep
29;387(13):1185
–
1195
.
46.
Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, et al. Effect of intermediate-dose
vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal
membrane
oxygenation
treatment,
or
mortality
among
patients
with
COVID-19
admitted
to
the
intensive
care
unit:
the
INSPIRATION
randomized
clinical
trial.
JAMA
.
2021
Apr
27;325(16):1620
–
1630
.
47.
Lemos AC, do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic
anticoagulation
for
severe
COVID-19:
a
randomized
phase
II
clinical
trial
(HESACOVID).
Thromb
Res
.
2020
Dec
1;196:359
–
366
.
48.
Jhund PS, Kondo T, Butt JH, et al. Dapagli
fl
ozin across the range of ejection fraction
in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and
DELIVER.
Nat
Med
.
2022
Sep;28(9):1956
–
1964
.
49.
Moskowitz A, Huang DT, Hou PC, et al. Effect of ascorbic acid, corticosteroids, and
thiamine on organ injury in septic shock: the ACTS randomized clinical trial.
JAMA
.
2020
Aug
18;324(7):642
–
650
.
50.
Oyer RA, Hurley P, Boehmer L, et al. Increasing racial and ethnic diversity in cancer
clinical
trials:
an
American
Society
of
Clinical
Oncology
and
Association
of
Community
Cancer
Centers
joint
research
statement.
J
Clin
Oncol
.
2022
Jul
1;
40(19):2163
–
2171
.
51.
van
der
Veen
A,
Brenkman
HJ,
Seesing
MF,
et
al.
Laparoscopic
versus
open
gastrectomy
for
gastric
cancer
(LOGICA):
a
multicenter
randomized
clinical
trial.
J
Clin
Oncol
.
2021
Mar;20(9):978
–
989
.
52.
Bell
G.
Talking
to
AI:
an
anthropological
encounter
with
arti
fi
cial
intelligence.
The
SAGE
Handbook
of
Cultural
Anthropology.
SAGE
Publications
Ltd.;
2021
Mar
31:
442
–
458.
vol.
1
.
53.
van
Assen
M,
Muscogiuri
E,
Tessarin
G,
De
Cecco
CN.
Arti
fi
cial
intelligence:
a
century-old
story.
In:
InArti
fi
cial
Intelligence
in
Cardiothoracic
Imaging
.
Cham:
Springer
International
Publishing;
2022
Apr
22:3
–
13
.
54.
Lee
RST,
Lee
RST.
AI
fundamentals.
Arti
fi
cial
intelligence
in
daily
life.
2020;156
.
55.
Luger
GF,
Luger
GF.
Modern
AI
and
how
we
got
hereKnowing
our
World:
An
Arti
fi
cial
Intelligence
Perspective
.
2021:49
–
74
.
56.
Chatterjee
R.
Fundamental
concepts
of
arti
fi
cial
intelligence
and
its
applications.
J
Math
Probl,
Equ
Stat
.
2020;1(2):13
–
24
.
57.
Kuipers M, Prasad R. Journey of artificial intelligence.
Wireless Pers Commun
. 2022;
123:3275
–
3290
.
58.
Benbya H, Davenport TH, Pachidi S. Arti
fi
cial intelligence in organizations: current
state
and
future
opportunities.
MIS
Q
Exec
.
2020;19(4):9
–
21
.
59.
Dissanayake
DMC.
Arti
fi
cial
intelligence
A
brief
overview
of
the
discipline
.
2021
.
60.
Lee
D,
Yoon
SN.
Application
of
arti
fi
cial
intelligence-based
technologies
in
the
healthcare
industry:
opportunities
and
challenges.
Int
J
Environ
Res
Publ
Health
.
2021
Jan;18(1):271
.
61.
Amann
J,
Blasimme
A,
Vayena
E,
Frey
D,
Madai
VI.
Precise4Q
Consortium.
Exploitability
for
arti
fi
cial
intelligence
in
healthcare:
a
multidisciplinary
perspective.
BMC
Med
Inf
Decis
Making
.
2020
Dec;20:1
–
9
.
62.
Habli I, Lawton T, Porter Z. Arti
fi
cial intelligence in health care: accountability and
safety.
Bull
World
Health
Organ
.
2020
Apr
4;98(4):251
.
63.
Muehlematter
UJ,
Daniore
P,
Vokinger
KN.
Approval
of
arti
fi
cial
intelligence
and
machine
learning-based
medical
devices
in
the
USA
and
Europe
(2015
–
20):
a
comparative
analysis.
The
Lancet
Digit
Health
.
2021
Mar
1;3(3):e195
–
e203
.
64.
Carter SM, Rogers W, Win KT, Frazer H, Richards B, Houssami N. The ethical, legal
and social implications of using arti
fi
cial intelligence systems in breast cancer care.
Breast
.
2020
Feb
1;49:25
–
32
.
65.
Naik
N,
Hameed
BM,
Shetty
DK,
et
al.
Legal
and
ethical
consideration
in
arti
fi
cial
intelligence
in
healthcare:
who
takes
responsibility?
Frontiers
in
surgery
.
2022
Mar
14;9:266
.
66.
Gerke
S,
Minssen
T,
Cohen
G.
Ethical
and
legal
challenges
of
arti
fi
cial
intelligence-
driven
healthcare.
Arti
fi
cial
intelligence
in
healthcare
.
2020:295
–
336
.
67.
Wolff
J,
Pauling
J,
Keck
A,
Baumbach
J.
The
economic
impact
of
arti
fi
cial
intelligence
in
health
care:
systematic
review.
J
Med
Internet
Res
.
2020
Feb
20;
22(2):e16866
.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
9
68.
Benjamens
S,
Dhunnoo
P,
Mesk
o
B.
The
state
of
arti
fi
cial
intelligence-based
FDA-
approved medical devices and algorithms: an online database.
NPJ Digit Med
. 2020
Sep
11;3(118)
.
69.
Safdar
NM,
Banja
JD,
Meltzer
CC.
Ethical
considerations
in
arti
fi
cial
intelligence.
European
J
Radiol
.
2020
Jan;122:108768
.
70.
Meszaros J, Minari J, Huys I. The future regulation of arti
fi
cial intelligence systems
in
healthcare
services
and
medical
research
in
the
European
Union.
Front
Genet
.
2022
Oct
4;13:927721
.
71.
Tzanou
M.
Personal
Data
Protection
and
Legal
Developments
in
the
European
Union
.
2020
.
72.
Forti M. The deployment of arti
fi
cial intelligence tools in the health sector: privacy
concerns
and
regulatory
answers
within
the
GDPR.
Eur
J
Legal
Stud
.
2021;13(1):
29
–
44
.
73.
Sartor
G,
Lagioia
F.
The
impact
of
the
general
data
protection
regulation
(GDPR)
on
arti
fi
cial
intelligence
.
2020
.
74.
Bak M, Madai VI, Fritzsche MC, Mayrhofer MT, McLennan S. You can
’
t have ai both
ways: balancing health data privacy and access fairly.
Front Genet
. 2022 Jun 13;13:
929453
.
75.
Hansen J, Wilson P, Verhoeven E, et al. Assessment of the EU Member States
’
rules
on
health
data
in
the
light
of
GDPR.
76.
Mourby M, Cathaoir K, Collin CB. Transparency of machine-learning
in healthcare:
the
GDPR
&
European
health
law.
Comput
Law
Secur
Rep
.
2021;43(105611)
.
77.
Estevez-Ordonez
D,
Abdelrashid
M,
Coffee
E,
et
al.
Racial
and
socioeconomic
disparities
in
glioblastoma
outcomes:
a
single-center,
retrospective
cohort
study.
Cancer
.
2023
Oct
1;129(19):3010
–
3022
.
78.
Harper
LJ,
Kidambi
P,
Kirincich
JM,
Thornton
JD,
Khatri
SB,
Culver
DA.
Health
disparities:
interventions
for
pulmonary
disease
–
A
narrative
review.
Chest
.
2023
Feb
27
Jul;164(1):179
–
189
.
79.
Snowden
LR,
Graaf
G,
Keyes
L,
Kitchens
K,
Ryan
A,
Wallace
N.
Did
Medicaid
expansion
close
African
American-white
health
care
disparities
nationwide?
A
scoping
review.
BMC
Publ
Health
.
2022
Aug
30;22(1):1638
.
80.
Ketchum FB, Erickson CM, Chin NA, et al. What in
fl
uences the willingness of Blacks
and
African
Americans
to
enroll
in
preclinical
Alzheimer
’
s
disease
biomarker
research?
A
qualitative
vignette
analysis.
J
Alzheim
Dis
.
2022
Jan
1;87(3):
1167
–
1179
.
81.
Hagiwara
N,
Duffy
C,
Quillin
J.
Implicit
and
explicit
racial
prejudice
and
stereotyping
toward
Black
(vs.
White)
Americans:
the
prevalence
and
variation
among
genetic
counselors
in
North
America.
J
Genet
Counsel
.
2023
Apr;32(2):
397
–
410
.
82.
Chowdhury-Paulino
IM,
Ericsson
C,
Vince
Jr
R,
Spratt
DE,
George
DJ,
Mucci
LA.
Racial disparities in prostate cancer among black men: epidemiology and outcomes.
Prostate
Cancer
Prostatic
Dis
.
2022
Sep;25(3):397
–
402
.
83.
Genevi
eve
LD,
Martani
A,
Wangmo
T,
Elger
BS.
Precision
public
health
and
structural
racism
in
the
United
States:
promoting
health
equity
in
the
COVID-19
pandemic
response.
JMIR
Publ
Health
Surveill
.
2022
Mar
4;8(3):e33277
.
84.
Liu
SR,
Glynn
LM.
The
contribution
of
racism-related
stress
and
adversity
to
disparities
in
birth
outcomes:
evidence
and
research
recommendations.
F
&
S
Reports
.
2022
Nov;3(2
Suppl):5
–
13
.
85.
Kordzadeh
N,
Ghasemaghaei
M.
Algorithmic
bias:
review,
synthesis,
and
future
research
directions.
Eur
J
Inf
Syst
.
2022
May
4;31(3):388
–
409
.
86.
Daneshjou
R,
Smith
MP,
Sun
MD,
Rotemberg
V,
Zou
J.
Lack
of
transparency
and
potential
bias
in
arti
fi
cial
intelligence
data
sets
and
algorithms:
a
scoping
review.
JAMA
Dermatol
.
2021
Nov
1;157(11):1362
–
1369
.
87.
Noseworthy PA, Attia ZI, Brewer LC, et al. Assessing and mitigating bias in medical
arti
fi
cial intelligence: the effects of race and ethnicity on a deep learning model for
ECG
analysis.
Circ:
Arrhythm
Electrophysiol
.
2020
Mar;13(3):e007988
.
88.
Seyyed-Kalantari
L,
Zhang
H,
McDermott
MB,
Chen
IY,
Ghassemi
M.
Underdiagnosis
bias
of
arti
fi
cial
intelligence
algorithms
applied
to
chest
radiographs
in
under-served
patient
populations.
Nat
Med
.
2021
Dec;27(12):
2176
–
2182
.
89.
Gerke
S.
Health
AI
for
good
rather
than
evil?
The
need
for
a
new
regulatory
framework
for
AI-based
medical
devices.
Yale
J.
Health
Pol
’
y
L.
&
Ethics
.
2021;
20(2):433
.
90.
Harvey
HB,
Gowda
V.
How
the
FDA
Regulates
AI
.
Academic
radiology;
2020
.
91.
Bretthauer
M,
Gerke
S,
Hassan
C,
Ahmad
OF,
Mori
Y.
The
new
European
medical
device
regulation:
balancing
innovation
and
patient
safety.
Ann
Intern
Med
.
2023
Jun;176(6):844
–
848
.
92.
Zanca
F,
Brusasco
C,
Pesapane
F,
Kwade
Z,
Beckers
R,
Avanzo
M.
Regulatory
aspects
of
the
use
of
arti
fi
cial
intelligence
medical
software.
In:
InSeminars
in
Radiation
Oncology
.
vol.
32.
WB
Saunders;
2022
Oct
1:432
–
441,
4
.
93.
Higgins
DC,
Johner
C.
Validation
of
arti
fi
cial
intelligence
containing
products
across
the
regulated
healthcare
industries.
Therapeutic
Innovation
&
Regulatory
Science
.
2023
Jul;57(4):797
–
809
.
94.
Sharma K, Manchikanti P. Regulation of arti
fi
cial intelligence in drug discovery and
health
care.
Biotechnol
Law
Rep
.
2020;39(5)
.
95.
Johnson
WG.
Flexible
regulation
for
dynamic
products?
The
case
of
applying
principles-based
regulation
to
medical
products
using
arti
fi
cial
intelligence.
Law.
96.
Liang
NL,
Chung
TK,
Vorp
DA.
The
regulatory
environment
for
arti
fi
cial
intelligence
enabled devices in the United States.
Semin Vasc
Surg
. 2023 Sep;36(3):
435
–
439
.
97.
Vatansever
S,
Schlessinger
A,
Wacker
D,
et
al.
Arti
fi
cial
intelligence
and
machine
learning-aided
drug
discovery
in
central
nervous
system
diseases:
state-of-the-arts
and
future
directions.
Med
Res
Rev
.
2021
May;41(3):1427
–
1473
.
98.
Sarkar
C,
Das
B,
Rawat
VS,
et
al.
Arti
fi
cial
intelligence
and
machine
learning
technology driven modern drug discovery and development.
Int J Mol Sci
. 2023 Jan
19;24(3):2026
.
99.
Dara
S,
Dhamercherla
S,
Jadav
SS,
Babu
CM,
Ahsan
MJ.
Machine
learning
in
drug
discovery:
a
review.
Artif
Intell
Rev
.
2022
Mar;55(3):1947
–
1999
.
100.
Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery.
Nature
.
2023
Apr;616(7958):673
–
685
.
101.
Gautam
V,
Gaurav
A,
Masand
N,
Lee
VS,
et
al.
Arti
fi
cial
intelligence
and
machine-
learning
approaches
in
structure
and
ligand-based
discovery
of
drugs
affecting
central
nervous
system.
Mol
Divers
.
2023
Apr;27(2):959
–
985
.
102.
Zhao
L,
Ciallella
HL,
Aleksunes
LM,
Zhu
H.
Advancing
computer-aided
drug
discovery
(CADD)
by
big
data
and
data-driven
machine
learning
modeling.
Drug
Discov
Today
.
2020
Sep;25(9):1624
–
1638
.
103.
Mouchlis
VD,
Afantitis
A,
Serra
A,
et
al.
Advances
in
de
novo
drug
design:
from
conventional
to
machine
learning
methods.
Int
J
Mol
Sci
.
2021
Feb
7;22(4):1676
.
104.
Shaker
B,
Ahmad
S,
Lee
J,
Jung
C,
Na
D.
In
silico
methods
and
tools
for
drug
discovery.
Comput
Biol
Med
.
2021
Oct
1;137:104851
.
105.
Carracedo-Reboredo P, Li
~
nares-Blanco J, Rodríguez-Fern
andez N, et al. A review on
machine learning approaches and trends in drug discovery.
Comput Struct Biotechnol
J
.
2021
Jan
1;19:4538
–
4558
.
106.
Jarada
TN,
Rokne
JG,
Alhajj
R.
A
review
of
computational
drug
repositioning:
strategies,
approaches,
opportunities,
challenges,
and
directions.
J
Cheminf
.
2020
Jul
22;12(1):46
.
107.
Lin X,
Li X,
Lin X.
A review
on applications
of computational
methods
in drug
screening
and
design.
Molecules
.
2020;25(6):1375,
18
.
108.
Cui
W,
Aouidate
A,
Wang
S,
Yu
Q,
Li
Y,
Yuan
S.
Discovering
anti-cancer
drugs
via
computational
methods.
Front
Pharmacol
.
2020
May
20;11:733
.
109.
Alanazi
SA,
Kamruzzaman
MM,
Alruwaili
M,
Alshammari
N,
Alqahtani
SA,
Karime
A.
Measuring
and
preventing
COVID-19
using
the
SIR
model
and
machine
learning
in
smart
health
care.
J
Healthc
Eng
.
2020;2020
.
110.
Selvaraj
C,
Chandra
I,
Singh
SK.
Arti
fi
cial
intelligence
and
machine
learning
approaches
for
drug
design:
challenges
and
opportunities
for
the
pharmaceutical
industries.
Mol
Divers
.
2021
Jun;26(3):1893
–
1913
.
111.
Meenakshi
DU,
Nandakumar
S,
Francis
AP,
et
al.
Deep
learning
and
site-speci
fi
c
drug
delivery:
the
future
and
intelligent
decision
support
for
pharmaceutical
manufacturing
science.
Deep
Learning
for
Targeted
Treatments:
Transformation
in
Healthcare
.
2022
Sep;16:1
–
38
.
112.
Walters
WP,
Barzilay
R.
Applications
of
deep
learning
in
molecule
generation
and
molecular
property
prediction.
Acc
Chem
Res
.
2020;54(2):263
–
270
.
113.
Bannigan
P,
Aldeghi
M,
Bao
Z,
H
€
ase
F,
Aspuru-Guzik
A,
Allen
C.
Machine
learning
directed
drug
formulation
development.
Adv
Drug
Deliv
Rev
.
2021
Aug
1;175:
113806
.
114.
Weissler
EH,
Naumann
T,
Andersson
T,
et
al.
The
role
of
machine
learning
in
clinical
research:
transforming
the
future
of
evidence
generation.
Trials
.
2021
Dec;
22:1
–
5
.
115.
Patel
L,
Shukla
T,
Huang
X,
Ussery
DW,
et
al.
Machine
learning
methods
in
drug
discovery.
Molecules
.
2020;25(22):5277,
12
.
116.
Elbadawi
M,
Gaisford
S,
Basit
AW.
Advanced
machine-learning
techniques
in
drug
discovery.
Drug
Discov
Today
.
2021
Mar;26(3):769
–
777
.
117.
Kumar
Attar
R,
Komal.
The
emergence
of
Natural
Language
Processing
(NLP)
techniques
in
healthcare
AI.
In:
InArti
fi
cial
Intelligence
for
Innovative
Healthcare
Informatics
.
Cham:
Springer
International
Publishing;
2022
May
24:285
–
307
.
118.
Liu S, Wang X, Hou
Y, et al. Multimodal data matters:
language model pre-training
over
structured
and
unstructured
electronic
health
records.
IEEE
J
Biomed
Health
Informatics
.
2022
Oct
28;27(1):504
–
514
.
119.
Zhou B, Yang G, Shi Z, Ma S. Natural language processing for smart healthcare.
IEEE
Rev
Biomed
Eng
.
2022
Sep;28(17):4
–
18
.
120.
Muralidharan C, Anitha R. Patient report analysis for identi
fi
cation and diagnosis of
disease.
Machine
Learning
for
Healthcare
.
2020:129
–
158
.
121.
Aladakatti SS, Senthil Kumar S. Exploring natural language processing techniques to
extract
semantics
from
unstructured
dataset
which
will
aid
in
effective
semantic
interlinking.
Int
J
Model,
Simulat,
Sci
Comput
.
2023
Feb
28;14(1):2243004
.
122.
Baviskar
D,
Ahirrao
S,
Potdar
V,
Kotecha
K.
Ef
fi
cient
automated
processing
of
the
unstructured
documents
using
arti
fi
cial
intelligence:
a
systematic
literature
review
and
future
directions.
IEEE
Access
.
2021.
PP(99):1-1
.
123.
Cherukuri
LS.
Advancing
personalized
medicine:
a
strategic
framework
for
integrating
NON-traditional
data
sources.
J
Comput
Eng
Technol
(IJCET)
.
2024;
15(1):7
–
15
.
124.
Banerjee
PS,
Chakraborty
B,
Anand
U,
Upadhyay
H.
Trainable
framework
for
information
extraction,
structuring
and
summarization
of
unstructured
data,
using
modi
fi
ed
NER.
Wireless
Pers
Commun
.
2021
Mar;117(2):769
–
807
.
125.
Fang
Y.
Design
and
Realization
of
Database
System
for
Judgement
Documents
Based
on
Natural
Language
Processing.
Database
.
2024,
6
–
1
.
126.
Rajesh
J,
Babu
PC.
Signi
fi
cance
of
natural
language
processing
in
data
analysis
using
business
intelligence.
In:
InDeep
Natural
Language
Processing
and
AI
Applications
for
Industry
5.0
.
IGI
Global;
2021:169
–
188
.
127.
Haleem
A,
Javaid
M,
Singh
RP,
Suman
R.
Medical
4.0
technologies
for
healthcare:
features,
capabilities,
and
applications.
Internet
of
Things
and
Cyber-Phys
Syst
.
2022
Jan
1;2:12
–
30
.
128.
Khang A, Abdullayev V, Hrybiuk O, Shukla AK.
Computer Vision and AI-Integrated IoT
Technologies
in
the
Medical
Ecosystem
.
2024
.
129.
Khang A, Abdullayev V, Ali RN, Bali SY, Mammadaga GM, Ha
fi
z MK. Using big data
to
solve
problems
in
the
fi
eld
of
medicine.
In:
InComputer
Vision
and
AI-Integrated
IoT
Technologies
in
the
Medical
Ecosystem
.
CRC
Press;
2024:407
–
418
.
130.
Sharma
A,
Kaur
J,
Singh
I.
Internet
of
things
(IoT)
in
pharmaceutical
manufacturing, warehousing, and supply chain
management.
SN Comput Sci
. 2020;
1(232)
.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
10
131.
Zakari
N,
Al-Razgan
M,
Alsaadi
A,
et
al.
Blockchain
technology
in
the
pharmaceutical
industry:
a
systematic
review.
PeerJ
Comput
Sci
.
2022
Mar
11;8:
e840
.
132.
Khang
A.
AI
and
IoT-Based
Technologies
for
Precision
Medicine
.
2023
.
133.
Rayhan
A,
Rayhan
R,
Rayhan
S.
The
Role
Of
AI
In
Healthcare:
Revolutionizing
Patient
Care
And
Well-Being.
doi:10.13140/RG.2.2.2023.
134.
Ghazal
TM,
Alshurideh
MT,
Alzoubi
HM.
Blockchain-enabled
internet
of
things
(IoT)
platforms
for
pharmaceutical
and
biomedical
research.
In:
The
International
Conference
on
Arti
fi
cial
Intelligence
and
Computer
Vision
.
vol.
29.
Cham:
Springer
International
Publishing;
2021
May:589
–
600
.
135.
Khang
A,
Rana
G,
Tailor
RK,
Abdullayev
V.
Data-centric
AI
solutions
and
emerging
technologies
in
the
healthcare
ecosystem
.
2023
.
136.
Svoboda P, Ghazal TM, A
fifi
MA, Kalra D, Alshurideh MT, Alzoubi HM.
Information
systems
integration
to
enhance
operational
customer
relationship
management
in
the
pharmaceutical
industry
.
InThe
International
Conference
on
Arti
fi
cial
Intelligence
and
Computer
Vision
.
Cham:
Springer
International
Publishing;
2021
May
29:553
–
572
.
137.
Ghazal TM, Hasan MK, Alshurideh MT, et al. IoT for smart cities: machine learning
approaches
in
smart healthcare
—
a
review.
Future
Internet
. 2021
Aug
23;13(8):218
.
138.
Khang A, Abdullayev V, Hrybiuk O, Shukla AK.
Computer vision and AI-integrated IoT
technologies
in
the
medical
ecosystem
.
2024
.
139.
Bashir
AK,
Victor
N,
Bhattacharya
S,
et
al.
Federated
learning
for
the
healthcare
metaverse:
concepts,
applications,
challenges,
and
future
directions.
IEEE
Internet
Things
J
.
2023
Aug
14.
PP(99)
.
140.
Sebastian
AM,
Peter
D.
Arti
fi
cial
intelligence
in
cancer
research:
trends,
challenges
and
future
directions.
Life
.
2022
Nov
28;12(12):1991
.
141.
Facchinetti
G,
Petrucci
G,
Albanesi
B,
De
Marinis
MG,
Piredda
M.
Can
smart
home
technologies
help
older
adults
manage
their
chronic
condition?
A
systematic
literature
review.
Int
J
Environ
Res
Publ
Health
.
2023
Jan
10;20(2):1205
.
142.
Kumar
S,
Underwood
SH,
Masters
JL,
et
al.
Ten
questions
concerning
smart
and
healthy built environments
for older adults.
Build Environ
. 2023 Oct 1;244:110720
.
143.
Agrebi S, Larbi A.
Use of arti
fi
cial intelligence in infectious diseases. Arti
fi
cial intelligence
in
precision
health
.
2020:415
–
438
.
144.
Xu
Y,
Liu
X,
Cao
X,
et
al.
Arti
fi
cial
intelligence:
a
powerful
paradigm
for
scienti
fi
c
research.
Innovation
.
2021
Nov
28;2(4)
.
145.
Srivani
M,
Murugappan
A,
Mala
T.
Cognitive
computing
technological
trends
and
future
research
directions
in
healthcare
—
a
systematic
literature
review.
Artif
Intell
Med
.
2023;138:102513
.
146.
Pradhan
B,
Bharti
D,
Chakravarty
S,
et
al.
Internet
of
things
and
robotics
in
transforming
current-day
healthcare
services.
J
Healthc
Eng
.
2021
May
26;2021:
1
–
5
.
147.
Ahmed
Z,
Mohamed
K,
Zeeshan
S,
Dong
XQ.
Arti
fi
cial
intelligence
with
multi-
functional
machine
learning
platform
development
for
better
healthcare
and
precision
medicine.
Database
.
2020,
1;2020:baaa010
.
148.
Sollini
M,
Bartoli
F,
Marciano
A,
Zanca
R,
Slart
RH,
Erba
PA.
Arti
fi
cial
intelligence
and
hybrid
imaging:
the
best
match
for
personalized
medicine
in
oncology.
European
J
Hybrid
Imaging
.
2020
Dec;4:1
–
22
.
149.
Quazi
S.
Arti
fi
cial
intelligence
and
machine
learning
in
precision
and
genomic
medicine.
Med
Oncol.
2022;39(8):120,
15
.
150.
Vadapalli S, Abdelhalim H, Zeeshan S, Ahmed Z. Arti
fi
cial intelligence and machine
learning
approaches
using
gene
expression
and
variant
data
for
personalized
medicine.
Brie
fi
ngs
Bioinf
.
2022
Sep;23(5):bbac191
.
151.
Hassan
M,
Awan
FM,
Naz
A,
et
al.
Innovations
in
genomics
and
big
data
analytics
for
personalized
medicine
and
health
care:
a
review.
Int
J
Mol
Sci
.
2022
Apr
22;
23(9):4645
.
152.
Bhinder
B,
Gilvary
C,
Madhukar
NS,
Elemento
O.
Arti
fi
cial
intelligence
in
cancer
research
and
precision
medicine.
Cancer
Discov
.
2021;11(4):900
–
915
.
153.
Jhawat
V,
Gupta
S,
Gulia
M,
Nair
A.
Arti
fi
cial
intelligence
and
data
science
in
pharmacogenomics-based
drug
discovery:
future
of
medicines.
Data
Science
for
Genomics
.
2023:85
–
97
.
154.
Dlamini Z, Francies FZ, Hull R, Marima R. Arti
fi
cial intelligence (AI) and big data in
cancer
and
precision
oncology.
Comput
Struct
Biotechnol
J
.
2020
Jan
1;18:
2300
–
2311
.
155.
Hamamoto
R,
Suvarna
K,
Yamada
M,
et
al.
Application
of
arti
fi
cial
intelligence
technology
in
oncology:
towards
the
establishment
of
precision
medicine.
Cancers
.
2020
Nov
26;12(12):3532
.
156.
Singh
AV,
Chandrasekar
V,
Paudel
N,
et
al.
Integrative
toxicogenomics:
advancing
precision
medicine
and
toxicology
through
arti
fi
cial
intelligence
and
OMICs
technology.
Biomed
Pharmacother
.
2023
Jul
1;163:114784
.
157.
Vora
LK,
Gholap
AD,
Jetha
K,
Thakur
RR,
Solanki
HK,
Chavda
VP.
Arti
fi
cial
intelligence
in
pharmaceutical technology
and drug delivery
design.
Pharmaceutics
.
2023
Jul
10;15(7):1916
.
158.
Alshawwa
SZ,
Kassem
AA,
Farid
RM,
Mostafa
SK,
Labib
GS.
Nanocarrier
drug
delivery
systems:
characterization,
limitations,
future
perspectives
and
implementation
of
arti
fi
cial
intelligence.
Pharmaceutics
.
2022
Apr
18;14(4):883
.
159.
Gao J,
Karp
JM, Langer
R,
Joshi N.
The
future of
drug
delivery.
Chem Mater
. 2023;
35(2):359
–
363,
24
.
160.
Sharma T, Mankoo A, Sood V. Arti
fi
cial intelligence in advanced pharmacy.
Int J Sci
Res
Archive
.
2021;2(1):47
–
54
.
161.
Wang W, Ye Z, Gao H, Ouyang D. Computational pharmaceutics-A new paradigm of
drug
delivery.
J
Contr
Release
.
2021;10(338):119
–
136
.
162.
Arden
NS,
Fisher
AC,
Tyner
K,
Lawrence
XY,
Lee
SL,
Kopcha
M.
Industry
4.0
for
pharmaceutical manufacturing: preparing for the smart factories of the future.
Int J
Pharm
.
2021
Jun
1;602:120554
.
163.
Kulkov
I.
The
role
of
arti
fi
cial
intelligence
in
business
transformation:
a
case
of
pharmaceutical
companies.
Technol
Soc
.
2021;66:101629
.
164.
Serov
N,
Vinogradov
V.
Arti
fi
cial
intelligence
to
bring
nanomedicine
to
life.
Adv
Drug
Deliv
Rev
.
2022;184:114194
.
165.
Egorov
E,
Pieters
C,
Korach-Rechtman
H,
Shklover
J,
Schroeder
A.
Robotics,
micro
fl
uidics,
nanotechnology
and
AI
in
the
synthesis
and
evaluation
of
liposomes
and
polymeric
drug
delivery
systems.
Drug
Delivery
Translat
Res
.
2021
Apr;11:
345
–
352
.
166.
Fruehwirt
W,
Duckworth
P.
Towards
better
healthcare:
what
could
and
should
be
automated?
Technol
Forecast
Soc
Change
.
2021;172:120967
.
167.
Tursunbayeva A, Renkema M. Arti
fi
cial intelligence in health-care: implications for
the
job
design
of
healthcare
professionals.
Asia
Pac
J
Hum
Resour
.
2023
Oct;61(4):
845
–
887
.
168.
Bohr A, Memarzadeh K. The rise of arti
fi
cial intelligence in healthcare applications.
In:
Arti
fi
cial
Intelligence
in
healthcare
.
2020:25
–
60
.
169.
Asan
O,
Choudhury
A.
Research
trends
in
arti
fi
cial
intelligence
applications
in
human factors health care: mapping review.
JMIR human factors
. 2021;8(2):e28236,
18
.
170.
Vall
es-Peris
N,
Barat-Auleda
O,
Dom
enech
M.
Robots
in
healthcare?
What
patients
say.
Int
J
Environ
Res
Publ
Health
.
2021
Sep
21;18(18):9933
.
171.
Willis
M,
Duckworth
P,
Coulter
A,
Meyer
ET,
Osborne
M.
Qualitative
and
quantitative approach to assess the potential for automating administrative tasks in
general
practice.
BMJ
Open
.
2020
Jun
1;10(6):e032412
.
172.
Alowais SA, Alghamdi SS, Alsuhebany N, et al. Revolutionizing healthcare: the role
of arti
fi
cial intelligence in clinical practice.
BMC Med Educ
. 2023 Sep 22;23(1):689
.
173.
Ilan
Y.
Improving
global
healthcare
and
reducing
costs
using
second-generation
arti
fi
cial
intelligence-based
digital
pills:
a
market
disruptor.
Int
J
Environ
Res
Publ
Health
.
2021
Jan;18(2):811
.
174.
Chopra
H, Baig
AA,
Gautam
RK, Kamal MA.
Application
of
arti
fi
cial intelligence
in
drug
discovery.
Curr
Pharmaceut
Des
.
2022
Sep
1;28(33):2690
–
2703
.
175.
Bhattamisra
SK,
Banerjee
P,
Gupta
P,
Mayuren
J,
Patra
S,
Candasamy
M.
Arti
fi
cial
intelligence
in
pharmaceutical
and
healthcare
research.
Big
Data
and
Cognitive
Computing
.
2023
Jan
11;7(1):10
.
176.
Chen Z, Liu X, Hogan W, Shenkman E, et al. Applications of arti
fi
cial intelligence in
drug
development
using
real-world
data.
Drug
Discov
Today
.
2021;26(5):
1256
–
1264
.
177.
Tripathi N, Goshisht MK, Sahu SK, Arora C. Applications of arti
fi
cial intelligence to
drug
design and discovery
in
the big data
era: a
comprehensive
review.
Mol Divers
.
2021;25(3):1643
–
1664
.
178.
Leite
ML,
de
Loiola
Costa
LS,
Cunha
VA,
et
al.
Arti
fi
cial
intelligence
and
the
future
of
life
sciences.
Drug
Discov
Today
.
2021
Nov
1;26(11):2515
–
2526
.
179.
Bao
C,
Singh
H,
Meyer
B,
Kirksey
K,
et
al.
Patient-provider
engagement
and
its
impact
on
health
outcomes:
a
longitudinal
study
of
patient
portal
use.
MIS
Q.2
.
2020;44
.
180.
Ross
EL,
Jamison
RN,
Nicholls
L,
Perry
BM,
Nolen
KD.
Clinical
integration
of
a
smartphone
app
for
patients
with
chronic
pain:
retrospective
analysis
of
predictors
of
bene
fi
ts
and
patient
engagement
between
clinic
visits.
J
Med
Internet
Res
.
2020
Apr
16;22(4):e16939
.
181.
Wei Y, Zheng P, Deng H, Wang X, Li X, Fu H. Design features for improving mobile
health
intervention
user
engagement:
systematic
review
and
thematic
analysis.
J
Med
Internet
Res
.
2020
Dec
9;22(12):e21687
.
182.
Iribarren
SJ,
Akande
TO,
Kamp
KJ,
Barry
D,
Kader
YG,
Suelzer
E.
Effectiveness
of
mobile
apps
to
promote
health
and
manage
disease:
systematic
review
and
meta-
analysis
of
randomized
controlled
trials.
JMIR
mHealth
and
uHealth
.
2021
Jan
11;
9(1):e21563
.
183.
Spaulding
EM,
Marvel
FA,
Piasecki
RJ,
Martin
SS,
Allen
JK.
User
engagement
with
smartphone
apps
and
cardiovascular
disease
risk
factor
outcomes:
systematic
review.
JMIR
cardio
.
2021
Feb
3;5(1):e18834
.
184.
Lyles
CR,
Nelson
EC,
Frampton
S,
Dykes
PC,
Cemballi
AG,
Sarkar
U.
Using
electronic
health
record
portals
to
improve
patient
engagement:
research
priorities
and
best
practices.
Ann
Intern
Med
.
2020
Jun
2;172(11_Supplement):S123
–
S129.
https://doi.org/10.7326/M19-0876
.
185.
B
€
ohm
AK,
Jensen
ML,
S
ø
rensen
MR,
Stargardt
T.
Real-world
evidence
of
user
engagement
with
mobile
health
for
diabetes
management:
longitudinal
observational
study.
JMIR
mHealth
and
uHealth
.
2020
Nov
6;8(11):e22212
.
186.
Liu
K,
Xie
Z,
Or
CK,
et
al.
Of
mobile
app-assisted
self-care
interventions
for
improving
patient
outcomes
in
type
2
diabetes
and/or
hypertension:
systematic
review
and
meta-analysis
of.
JMIR
mHealth
and
uHealth
.
2020;8(8):e15779
.
187.
Ghose
A,
Guo
X,
Li
B,
Dang
Y.
Empowering
patients
using
smart
mobile
health
platforms:
evidence
from
a
randomized
fi
eld
experiment.
arXiv
preprint
arXiv:
2102.05506
.
2021
.
188.
Amjad
A,
Kordel
P,
Fernandes
G.
A
review
on
innovation
in
healthcare
sector
(telehealth)
through
arti
fi
cial
intelligence.
Sustainability
.
2023;15(6655):1
–
24
.
189.
Baum
ZJ,
Yu
X,
Ayala
PY,
Zhao
Y,
Watkins
SP,
Zhou
Q.
Arti
fi
cial
intelligence
in
chemistry:
current
trends
and
future
directions.
J
Chem
Inf
Model
.
2021
Jul
15;
61(7):3197
–
3212
.
190.
Ghaffar
Nia
N,
Kaplanoglu
E,
Nasab
A.
Evaluation
of
arti
fi
cial
intelligence
techniques
in
disease
diagnosis
and
prediction.
Discov
Artif
Intell
.
2023;3(5)
.
191.
Makimoto H, Kohro T. Adopting arti
fi
cial intelligence in cardiovascular medicine: a
scoping
review.
Hypertens
Res
.
2024;47(3):685
–
699
.
192.
Albahri
AS,
Duhaim
AM,
Fadhel
MA,
et al.
A
systematic
review
of
trustworthy
and
explainable arti
fi
cial intelligence in healthcare: assessment of quality, bias risk, and
data
fusion.
Inf
Fusion
.
2023
Mar
15;96:156
–
191
.
193.
Li
Z,
Koban
KC,
Schenck
TL,
Giunta
RE,
Li
Q,
Sun
Y.
Arti
fi
cial
intelligence
in
dermatology
image
analysis:
current
developments
and
future
trends.
J
Clin
Med
.
2022
Nov
18;11(22):6826
.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
11
194.
Joksimovic
S,
Ifenthaler
D,
Marrone
R,
De
Laat
M,
Siemens
G.
Opportunities
of
arti
fi
cial
intelligence
for
supporting
complex
problem-solving:
fi
ndings
from
a
scoping
review.
Comput
Educ:
Artif
Intell
.
2023
May
1:100138
.
195.
Kumar
M, Nguyen
TN, Kaur J,
et al. Opportunities
and challenges
in application of
arti
fi
cial
intelligence
in
pharmacology.
Pharmacol
Rep
.
2023
Feb;75(1):3
–
18
.
196.
Kakhi
K,
Alizadehsani
R,
Kabir
HD,
Khosravi
A,
Nahavandi
S,
Acharya
UR.
The
internet
of
medical
things
and
arti
fi
cial
intelligence:
trends,
challenges,
and
opportunities.
Biocybern
Biomed
Eng
.
2022
Jul
1;42(3):749
–
771
.
197.
Davis AM, Engkvist O, Fairclough RJ, Feierberg I, Freeman A, Iyer P. Public-private
partnerships: compound and data sharing in drug discovery and development.
SLAS
DISCOVERY:
Adv
Sci
Drug
Discov
.
2021
Jun;26(5):604
–
619
.
198.
Romasanta
AK,
van
der
Sijde
PC,
Smit
MJ,
de
Esch
IJ,
Jahnke
W,
van
Muijlwijk-
Koezen
JE.
Career
development
in
fragment-based
drug
discovery.
Drug
Discov
Today
Technol
.
2020
Dec
1;37:107
–
116
.
S.
Aritra
et
al.
Intelligent
Pharmacy
xxx
(xxxx)
xxx
12